77. 下垂体性成長ホルモン分泌亢進症 Disease details / Clinical trials / Drug dev / DR info

1H/31P magnetic resonance spectroscopy
   Medical University of Vienna
      2014   -   NCT02115906   Austria
76517-01-4
   Department of Internal Medicine of the University of Munich
      2007   -   EUCTR2007-005585-12-DE   Germany
81409-90-7
   Department of Internal Medicine of the University of Munich
      2007   -   EUCTR2007-005585-12-DE   Germany
   NOVARTIS FARMA
      2007   -   EUCTR2005-005852-42-IT   Italy;Portugal
   Novartis Pharma Services AG
      2008   -   EUCTR2005-005852-42-PT   Italy;Portugal
      2007   Phase 4   EUCTR2005-005852-42-BE   Belgium;Italy;Portugal
   Österreichisches Akromegalie Register
      2014   -   EUCTR2010-023674-39-AT   Austria
Acetaminophen
   Huashan Hospital
      2020   -   NCT04529356   -
Acetato DE octreótida
   Indevus Pharmaceuticals Incorporated
      2009   -   EUCTR2008-003327-23-ES   Czech Republic;Hungary;Poland;Spain
Adipose tissue biopsy
   Columbia University
      2003   -   NCT01809808   United States
Alesse
   Université de Montréal
      2006   Phase 2   NCT00315107   Canada
ATL1103
   Antisense Therapeutics Ltd
      2013   -   EUCTR2012-003147-30-HU   Hungary;Spain;United Kingdom
      2013   -   EUCTR2012-003147-30-ES   Hungary;Spain;United Kingdom
      2012   Phase 2   EUCTR2012-003147-30-GB   Hungary;Spain;United Kingdom
Avandia*28CPR RIV 4MG
   AZIENDA OSPEDALIERA PISANA
      2007   -   EUCTR2007-005568-28-IT   Italy
BIM 23a760
   Ipsen
      2009   Phase 2   NCT00994214   Belgium;Brazil;Canada;Czech Republic;Czechia;France;Germany;Italy;Latvia;Lithuania;Mexico;Netherlands;Poland;Romania;Russian Federation;Sweden;Ukraine;United Kingdom;United States
   Ipsen Pharma
      2010   -   EUCTR2009-010787-42-PL   Belgium;Czech Republic;France;Germany;Italy;Latvia;Lithuania;Netherlands;Poland;Sweden;United Kingdom
      2010   -   EUCTR2009-010787-42-NL   Belgium;Czech Republic;France;Germany;Italy;Latvia;Lithuania;Netherlands;Poland;Sweden;United Kingdom
      2010   -   EUCTR2009-010787-42-CZ   Belgium;Czech Republic;France;Germany;Italy;Latvia;Lithuania;Netherlands;Poland;Sweden;United Kingdom
      2009   -   EUCTR2009-010787-42-SE   Belgium;Czech Republic;France;Germany;Italy;Latvia;Lithuania;Netherlands;Poland;Sweden;United Kingdom
      2009   -   EUCTR2009-010787-42-LV   Belgium;Czech Republic;France;Germany;Italy;Latvia;Lithuania;Netherlands;Poland;Sweden;United Kingdom
      2009   -   EUCTR2009-010787-42-LT   Belgium;Czech Republic;France;Germany;Italy;Latvia;Lithuania;Netherlands;Poland;Sweden;United Kingdom
      2009   -   EUCTR2009-010787-42-GB   Belgium;Czech Republic;France;Germany;Italy;Latvia;Lithuania;Netherlands;Poland;Sweden;United Kingdom
      2009   Phase 2   EUCTR2009-010787-42-FR   Belgium;Czech Republic;France;Germany;Italy;Latvia;Lithuania;Netherlands;Poland;Sweden;United Kingdom
      2009   -   EUCTR2009-010787-42-BE   Belgium;Czech Republic;France;Germany;Italy;Latvia;Lithuania;Netherlands;Poland;Sweden;United Kingdom
      -   -   EUCTR2009-010787-42-DE   Belgium;Czech Republic;France;Germany;Italy;Latvia;Lithuania;Netherlands;Poland;Sweden;United Kingdom
BIM23a760
   BEAUFOUR IPSEN PHARMA
      2009   -   EUCTR2009-010787-42-IT   Belgium;Czech Republic;France;Germany;Italy;Latvia;Lithuania;Netherlands;Poland;Sweden;United Kingdom
      2008   -   EUCTR2008-000500-83-IT   Belgium;Italy;Latvia;Lithuania
   Beaufour Ipsen Pharma
      2008   -   EUCTR2008-000500-83-LV   Belgium;Italy;Latvia;Lithuania
   Ipsen Pharma
      2010   -   EUCTR2009-010787-42-CZ   Belgium;Czech Republic;France;Germany;Italy;Latvia;Lithuania;Netherlands;Poland;Sweden;United Kingdom
      2008   -   EUCTR2008-000500-83-LT   Belgium;Italy;Latvia;Lithuania
   Ipsen Pharma SAS
      2008   -   EUCTR2008-000500-83-BE   Belgium;Italy;Latvia;Lithuania
BIM23b065
   Ipsen
      2017   Phase 2   NCT03045302   Belarus;Belgium;Bulgaria;Hungary;Serbia;Ukraine
   Ipsen Pharma SAS
      2017   Phase 2   EUCTR2015-003868-37-BG   Belarus;Belgium;Bulgaria;Hungary;Serbia;Ukraine
      2016   Phase 2   EUCTR2015-003868-37-HU   Belarus;Belgium;Bulgaria;Hungary;Serbia;Ukraine
      2016   Phase 2   EUCTR2015-003868-37-BE   Belarus;Belgium;Bulgaria;Hungary;Serbia;Ukraine
Blood tests: IGF-1, AST/ALT/ALP/tbil, GTT
   Pfizer
      2004   Phase 4   NCT00151437   Canada
C2L-OCT-01 PR
   Ambrilia Biopharma Inc.
      2007   Phase 3   EUCTR2006-005855-14-SK   Hungary;Slovakia
      2007   -   EUCTR2006-005855-14-HU   Hungary
C2L-OCT-01 PR , 10MG
   Ambrilia Biopharma Inc.
      2008   Phase 3   EUCTR2007-004320-21-SK   Hungary;Slovakia
   Mallinckrodt Inc.
      2007   -   EUCTR2007-004162-41-HU   Hungary
C2L-OCT-01 PR , 20MG
   Ambrilia Biopharma Inc.
      2008   Phase 3   EUCTR2007-004320-21-SK   Hungary;Slovakia
      2007   -   EUCTR2007-004320-21-HU   Hungary
   Mallinckrodt Inc.
      2007   -   EUCTR2007-004162-41-HU   Hungary
C2L-OCT-01 PR , 30MG
   Ambrilia Biopharma Inc.
      2008   Phase 3   EUCTR2007-004320-21-SK   Hungary;Slovakia
      2007   -   EUCTR2007-004320-21-HU   Hungary
   Mallinckrodt Inc.
      2007   -   EUCTR2007-004162-41-HU   Hungary
C2L-OCT-01 PR 30 MG
   Ambrilia Biopharma, Inc.
      2007   Phase 3   NCT00635765   Belarus;Former Serbia and Montenegro;Hungary;Romania;Serbia;Slovakia;Ukraine
C2L-OCT-01 PR, 10 or 20 MG
   Ambrilia Biopharma, Inc.
      2008   Phase 3   NCT00642421   Belarus;Former Serbia and Montenegro;Hungary;Romania;Serbia;Ukraine;United States
C2L-OCT-01 PR, 20 MG
   Ambrilia Biopharma, Inc.
      2008   Phase 3   NCT00642421   Belarus;Former Serbia and Montenegro;Hungary;Romania;Serbia;Ukraine;United States
C2L-OCT-01 PR, 30 MG
   Ambrilia Biopharma, Inc.
      2007   Phase 3   NCT00616551   Belarus;Former Serbia and Montenegro;Hungary;Romania;Serbia;Slovakia;Ukraine
Cabaser
   Christie Hospital
      2008   -   EUCTR2006-000344-10-IE   Ireland;United Kingdom
Cabergolin
   Novartis Pharma GmbH
      2006   -   EUCTR2005-002919-24-DE   Germany
Cabergoline
   Chiasma, Inc.
      2016   Phase 3   NCT02685709   Austria;France;Germany;Hungary;Italy;Lithuania;Poland;Romania;Russian Federation;Serbia;Spain;United Kingdom;United States
   Christie Hospital
      2008   -   EUCTR2006-000344-10-IE   Ireland;United Kingdom
      2006   Phase 4   EUCTR2006-000344-10-GB   Ireland;United Kingdom
   Department of Internal Medicine of the University of Munich
      2007   -   EUCTR2007-005585-12-DE   Germany
   Federal University of São Paulo
      2005   -   NCT01014793   Brazil
   NOVARTIS FARMA
      2007   -   EUCTR2005-005852-42-IT   Italy;Portugal
   Novartis Pharma Services AG
      2008   -   EUCTR2005-005852-42-PT   Italy;Portugal
      2007   Phase 4   EUCTR2005-005852-42-BE   Belgium;Italy;Portugal
   Novartis Pharmaceuticals
      2006   Phase 4   NCT01278342   France;Italy;Poland;Portugal;Switzerland
   RECORDATI GROUP
      2013   Phase 4   NCT01794793   Argentina;Belgium;Brazil;Bulgaria;Canada;China;France;Germany;Greece;Hungary;India;Israel;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;Peru;Poland;Portugal;Romania;Russian Federation;Spain;Switzerland;Taiwan;Thailand;Turkey;United States
   Österreichisches Akromegalie Register
      2014   -   EUCTR2010-023674-39-AT   Austria
CAM2029
   Camurus AB
      2020   Phase 3   EUCTR2019-002190-66-IT   Bulgaria;Germany;Greece;Hungary;Italy;Poland;Russian Federation;Spain;Sweden;Turkey;United Kingdom;United States
      2020   Phase 3   EUCTR2019-002190-66-GB   Bulgaria;Germany;Greece;Hungary;Italy;Netherlands;Poland;Russian Federation;Serbia;Spain;Sweden;Turkey;United Kingdom;United States
      2020   Phase 3   EUCTR2019-002190-66-ES   Bulgaria;Germany;Greece;Hungary;Italy;Netherlands;Poland;Russian Federation;Serbia;Spain;Sweden;Turkey;United Kingdom;United States
      2020   Phase 3   EUCTR2019-001191-11-IT   Bulgaria;Germany;Greece;Hungary;Italy;Netherlands;Poland;Russian Federation;Spain;Sweden;Turkey;United Kingdom;United States
      2020   Phase 3   EUCTR2019-001191-11-GB   Bulgaria;Germany;Greece;Hungary;Italy;Netherlands;Poland;Russian Federation;Serbia;Spain;Sweden;Turkey;United Kingdom;United States
      2020   Phase 3   EUCTR2019-001191-11-ES   Bulgaria;Germany;Greece;Hungary;Italy;Netherlands;Poland;Russian Federation;Serbia;Spain;Sweden;Turkey;United Kingdom;United States
      2020   Phase 3   EUCTR2019-001191-11-DE   Germany;Greece;Hungary;Italy;Poland;Russian Federation;Spain;Sweden;Turkey;United Kingdom;United States
      2019   Phase 3   NCT04125836   Germany;Greece;Hungary;Italy;Poland;Russian Federation;Serbia;Spain;Turkey;United Kingdom;United States
      2019   Phase 3   NCT04076462   Germany;Greece;Hungary;Italy;Poland;Russian Federation;Spain;Turkey;United Kingdom;United States
      2019   Phase 3   EUCTR2019-002190-66-HU   Bulgaria;Germany;Greece;Hungary;Italy;Netherlands;Poland;Russian Federation;Serbia;Spain;Sweden;Turkey;United Kingdom;United States
      2019   Phase 3   EUCTR2019-001191-11-PL   Bulgaria;Germany;Greece;Hungary;Italy;Netherlands;Poland;Russian Federation;Serbia;Spain;Sweden;Turkey;United Kingdom;United States
      2019   Phase 3   EUCTR2019-001191-11-HU   Bulgaria;Germany;Greece;Hungary;Italy;Netherlands;Poland;Russian Federation;Serbia;Spain;Sweden;Turkey;United Kingdom;United States
      2019   Phase 3   EUCTR2019-001191-11-GR   Germany;Greece;Hungary;Italy;Poland;Russian Federation;Spain;Sweden;Turkey;United Kingdom;United States
CAM2029 (octreotide subcutaneous depot) _prefilled syringe_prefilled syringe
   Camurus AB
      2020   Phase 3   EUCTR2019-002190-66-DE   Germany;Greece;Hungary;Italy;Poland;Russian Federation;Serbia;Spain;Türkiye;United Kingdom;United States
CAM2029 (octreotide subcutaneous depot)_ prefilled PEN
   Camurus AB
      2020   Phase 3   EUCTR2019-002190-66-DE   Germany;Greece;Hungary;Italy;Poland;Russian Federation;Serbia;Spain;Türkiye;United Kingdom;United States
CAM2029 (octreotide subcutaneous depot)_ prefilled syringe
   Camurus AB
      2020   Phase 3   EUCTR2019-002190-66-DE   Germany;Greece;Hungary;Italy;Poland;Russian Federation;Serbia;Spain;Türkiye;United Kingdom;United States
CAM2029 (octreotide subcutaneous depot)_pre-filled PEN
   Camurus AB
      2019   Phase 3   EUCTR2019-002190-66-GR   Germany;Greece;Hungary;Italy;Poland;Russian Federation;Serbia;Spain;Turkey;United Kingdom;United States
CAM2029 (octreotide subcutaneous depot)_pre-filled syringe
   Camurus AB
      2019   Phase 3   EUCTR2019-002190-66-GR   Germany;Greece;Hungary;Italy;Poland;Russian Federation;Serbia;Spain;Turkey;United Kingdom;United States
CAM2029 (octreotide subcutaneous depot)_prefilled PEN
   Camurus AB
      2019   Phase 3   EUCTR2019-002190-66-PL   Germany;Greece;Hungary;Italy;Poland;Russian Federation;Serbia;Spain;Turkey;United Kingdom;United States
CAM2029 (octreotide subcutaneous depot)_prefilled syringe
   Camurus AB
      2019   Phase 3   EUCTR2019-002190-66-PL   Germany;Greece;Hungary;Italy;Poland;Russian Federation;Serbia;Spain;Turkey;United Kingdom;United States
CAM2029-BR
   Camurus AB
      2014   -   EUCTR2013-000533-12-IT   Germany;Italy
      2014   Phase 2   EUCTR2013-000533-12-DE   Germany;Italy
Cialis - 20 MG 2 compresse rivestite CON film IN blister USO orale
   UMBERTO I - POLICLINICO DI ROMA
      2016   Phase 2   EUCTR2015-004498-34-IT   Italy
Clomiphene citrate
   Felipe Henning Gaia Duarte
      2011   Phase 2   NCT02274311   -
Cmri
   Assistance Publique - Hôpitaux de Paris
      2014   -   NCT02948322   France
Combination with dopamine agonist cabergoline
   Ludwig-Maximilians - University of Munich
      2008   Phase 4   NCT00595140   Germany
Combination with somatostatin analogue octreotide
   Ludwig-Maximilians - University of Munich
      2008   Phase 4   NCT00595140   Germany
CRN00808
   Crinetics Pharmaceuticals, Inc.
      2022   Phase 3   EUCTR2021-001703-32-PL   Argentina;Brazil;Bulgaria;China;France;Germany;Greece;Hungary;India;Israel;Italy;Peru;Poland;Spain;United Kingdom;United States
      2022   Phase 3   EUCTR2021-001703-32-IT   Argentina;Brazil;Bulgaria;China;France;Germany;Greece;Hungary;India;Italy;Peru;Poland;Russian Federation;Spain;United Kingdom;United States
      2022   Phase 3   EUCTR2021-001703-32-GR   Argentina;Brazil;Bulgaria;China;France;Germany;Greece;Hungary;India;Israel;Italy;Peru;Poland;Spain;United Kingdom;United States
      2022   Phase 3   EUCTR2021-001703-32-ES   Argentina;Brazil;Bulgaria;China;France;Germany;Greece;Hungary;India;Italy;Peru;Poland;Russian Federation;Spain;United Kingdom;United States
      2022   Phase 3   EUCTR2021-001703-32-BG   Argentina;Brazil;Bulgaria;China;France;Germany;Greece;Hungary;India;Israel;Italy;Peru;Poland;Spain;United Kingdom;United States
      2022   Phase 3   EUCTR2020-005431-70-BE   Argentina;Austria;Belgium;Brazil;Bulgaria;France;Germany;Hungary;Israel;Italy;Peru;Poland;Russian Federation;Serbia;Spain;United Kingdom;United States
      2021   Phase 3   EUCTR2020-005431-70-PL   Argentina;Austria;Belgium;Brazil;Bulgaria;France;Germany;Hungary;Israel;Italy;Peru;Poland;Russian Federation;Serbia;Spain;United Kingdom;United States
      2021   Phase 3   EUCTR2020-005431-70-IT   Argentina;Austria;Belgium;Brazil;Bulgaria;France;Germany;Hungary;Israel;Italy;Peru;Poland;Russian Federation;Serbia;Spain;United Kingdom;United States
      2021   Phase 3   EUCTR2020-005431-70-HU   Argentina;Austria;Belgium;Brazil;Bulgaria;France;Germany;Hungary;Israel;Italy;Peru;Poland;Russian Federation;Serbia;Spain;United Kingdom;United States
      2021   Phase 3   EUCTR2020-005431-70-ES   Argentina;Austria;Belgium;Brazil;Bulgaria;France;Germany;Hungary;Israel;Italy;Peru;Poland;Russian Federation;Serbia;Spain;United Kingdom;United States
      2021   Phase 3   EUCTR2020-005431-70-DE   Argentina;Austria;Belgium;Brazil;Bulgaria;France;Germany;Hungary;Israel;Italy;Peru;Poland;Russian Federation;Serbia;Spain;United Kingdom;United States
      2021   Phase 3   EUCTR2020-005431-70-AT   Argentina;Austria;Belgium;Brazil;Bulgaria;France;Germany;Hungary;Israel;Italy;Peru;Poland;Russian Federation;Serbia;Spain;United Kingdom;United States
      2020   Phase 2   EUCTR2019-002193-31-SK   Brazil;Germany;Greece;Hungary;Serbia;Slovakia;United Kingdom;United States
      2020   Phase 2   EUCTR2019-002193-31-HU   Australia;Brazil;Germany;Greece;Hungary;Italy;New Zealand;Poland;Romania;Serbia;Slovakia;United Kingdom;United States
      2020   Phase 2   EUCTR2019-002193-31-GR   Brazil;Germany;Greece;Hungary;Romania;Serbia;Slovakia;United Kingdom;United States
CRN00808 IS AN oral NON-peptide small molecule somatostatin receptor 2 (SST2) agonist
   Crinetics Pharmaceuticals, Inc.
      2019   Phase 2   EUCTR2018-002230-20-IT   Germany;Greece;Hungary;Italy;Poland;Romania;Russian Federation;Serbia;Slovakia;United Kingdom;United States
      2019   Phase 2   EUCTR2018-001833-42-IT   Germany;Greece;Hungary;Italy;Poland;Romania;Russian Federation;Serbia;Slovakia;United Kingdom;United States
CRN00808 è UN agonista DEL recettore 2 della somatostatina (SST2), orale, NON peptidico A piccole dimensioni molecolari
   Crinetics Pharmaceuticals, Inc.
      2019   Phase 2   EUCTR2018-001833-42-IT   Germany;Greece;Hungary;Italy;Poland;Romania;Russian Federation;Serbia;Slovakia;United Kingdom;United States
CRN00808.HCL
   Crinetics Pharmaceuticals, Inc.
      2019   Phase 2   EUCTR2018-002230-20-PL   Germany;Greece;Hungary;Italy;Poland;Romania;Russian Federation;Serbia;Slovakia;United Kingdom;United States
      2019   Phase 2   EUCTR2018-002230-20-IT   Germany;Greece;Hungary;Italy;Poland;Romania;Russian Federation;Serbia;Slovakia;United Kingdom;United States
      2019   Phase 2   EUCTR2018-002230-20-GR   Australia;Germany;Greece;Hungary;Italy;Poland;Romania;Serbia;Slovakia;United Kingdom;United States
      2019   Phase 2   EUCTR2018-002230-20-GB   Australia;Germany;Greece;Hungary;Italy;Poland;Romania;Serbia;Slovakia;United Kingdom;United States
      2019   Phase 2   EUCTR2018-002230-20-DE   Australia;Germany;Greece;Hungary;Italy;Poland;Romania;Serbia;Slovakia;United Kingdom;United States
      2019   Phase 2   EUCTR2018-001833-42-PL   Australia;Germany;Greece;Hungary;Italy;Poland;Romania;Serbia;Slovakia;United Kingdom;United States
      2019   Phase 2   EUCTR2018-001833-42-IT   Germany;Greece;Hungary;Italy;Poland;Romania;Russian Federation;Serbia;Slovakia;United Kingdom;United States
      2019   Phase 2   EUCTR2018-001833-42-GR   Germany;Greece;Hungary;Italy;Poland;Romania;Russian Federation;Serbia;Slovakia;United Kingdom;United States
      2019   Phase 2   EUCTR2018-001833-42-GB   Australia;Germany;Greece;Hungary;Italy;Poland;Romania;Serbia;Slovakia;United Kingdom;United States
      2018   Phase 2   EUCTR2018-002230-20-SK   Australia;Germany;Greece;Hungary;Italy;Poland;Romania;Serbia;Slovakia;United Kingdom;United States
      2018   Phase 2   EUCTR2018-002230-20-HU   Germany;Greece;Hungary;Italy;Poland;Romania;Russian Federation;Serbia;Slovakia;United Kingdom;United States
      2018   Phase 2   EUCTR2018-001833-42-SK   Australia;Germany;Greece;Hungary;Italy;Poland;Romania;Serbia;Slovakia;United Kingdom;United States
      2018   Phase 2   EUCTR2018-001833-42-HU   Germany;Greece;Hungary;Italy;Poland;Romania;Russian Federation;Serbia;Slovakia;United Kingdom;United States
Cyclo ((diaminoethyl-carbamate)hypro-PHG-(D) TRP-LY pamoate
   Novartis Farmacéutica, S. A
      2008   Phase 3   EUCTR2007-001972-36-ES   Belgium;Czech Republic;Denmark;France;Germany;Greece;Hungary;Italy;Netherlands;Poland;Portugal;Spain;Sweden;United Kingdom
Cyclo((diaminoethyl-carbamate)hypro-PHG-(D)TRP-LY pamoate
   Novartis Pharma Services AG
      2009   -   EUCTR2007-001972-36-PT   Belgium;Czech Republic;Denmark;France;Germany;Greece;Hungary;Italy;Netherlands;Poland;Portugal;Spain;Sweden;United Kingdom
      2009   Phase 3   EUCTR2007-001972-36-GB   Belgium;Czech Republic;Denmark;France;Germany;Greece;Hungary;Italy;Netherlands;Poland;Portugal;Spain;Sweden;United Kingdom
      2008   Phase 3   EUCTR2007-001972-36-SE   Belgium;Czech Republic;Denmark;France;Germany;Greece;Hungary;Italy;Netherlands;Poland;Portugal;Spain;Sweden;United Kingdom
      2008   Phase 3   EUCTR2007-001972-36-NL   Belgium;Czech Republic;Denmark;France;Germany;Greece;Hungary;Italy;Netherlands;Poland;Portugal;Spain;Sweden;United Kingdom
      2008   Phase 3   EUCTR2007-001972-36-HU   Belgium;Czech Republic;Denmark;France;Germany;Greece;Hungary;Italy;Netherlands;Poland;Portugal;Spain;Sweden;United Kingdom
      2008   Phase 3   EUCTR2007-001972-36-GR   Belgium;Czech Republic;Denmark;France;Germany;Greece;Hungary;Italy;Netherlands;Poland;Portugal;Spain;Sweden;United Kingdom
      2008   -   EUCTR2007-001972-36-DK   Belgium;Czech Republic;Denmark;France;Germany;Greece;Hungary;Italy;Netherlands;Poland;Portugal;Spain;Sweden;United Kingdom
      2008   Phase 3   EUCTR2007-001972-36-BE   Belgium;Czech Republic;Denmark;France;Germany;Greece;Hungary;Italy;Netherlands;Poland;Portugal;Spain;Sweden;United Kingdom
      2007   Phase 3   EUCTR2007-001972-36-CZ   Belgium;Czech Republic;Denmark;France;Germany;Greece;Hungary;Italy;Netherlands;Poland;Portugal;Spain;Sweden;United Kingdom
Cyclo((diaminoethyl-carbamate)hypro-PHG-(D)TRP-LYS pamoate
   Novartis Pharma Services AG
      2008   Phase 3   EUCTR2007-001972-36-PL   Belgium;Czech Republic;Denmark;France;Germany;Greece;Hungary;Italy;Netherlands;Poland;Portugal;Spain;Sweden;United Kingdom
Cyclo((diaminoethyl-carbamate)hypro-PHG-(D)TRP-LYS-TYR(BZL)-PHE) pamoate
   Novartis Farmacéutica, S.A.
      2010   Phase 3   EUCTR2009-016722-13-ES   Belgium;France;Germany;Italy;Norway;Poland;Spain;United Kingdom
   Novartis Pharma Services AG
      2012   Phase 3   EUCTR2009-016722-13-GB   Argentina;Belgium;Brazil;France;Germany;Israel;Italy;Mexico;Norway;Poland;Spain;United Kingdom;United States
      2011   Phase 3   EUCTR2009-016722-13-PL   Argentina;Belgium;Brazil;France;Germany;Israel;Italy;Mexico;Norway;Poland;Spain;United Kingdom;United States
      2011   Phase 3   EUCTR2009-016722-13-NO   Belgium;France;Germany;Italy;Norway;Poland;Spain;United Kingdom
      2010   Phase 3   EUCTR2009-016722-13-FR   Belgium;France;Germany;Italy;Norway;Poland;Spain;United Kingdom
      2010   Phase 3   EUCTR2009-016722-13-DE   Argentina;Belgium;Brazil;France;Germany;Israel;Italy;Mexico;Norway;Poland;Spain;United Kingdom;United States
      2010   Phase 3   EUCTR2009-016722-13-BE   Argentina;Belgium;Brazil;France;Germany;Israel;Italy;Mexico;Norway;Poland;Spain;United Kingdom;United States
      2009   -   EUCTR2007-001972-36-PT   Belgium;Czech Republic;Denmark;France;Germany;Greece;Hungary;Italy;Netherlands;Poland;Portugal;Spain;Sweden;United Kingdom
      2009   Phase 3   EUCTR2007-001972-36-GB   Belgium;Czech Republic;Denmark;France;Germany;Greece;Hungary;Italy;Netherlands;Poland;Portugal;Spain;Sweden;United Kingdom
      2008   Phase 3   EUCTR2007-001972-36-SE   Belgium;Czech Republic;Denmark;France;Germany;Greece;Hungary;Italy;Netherlands;Poland;Portugal;Spain;Sweden;United Kingdom
      2008   Phase 3   EUCTR2007-001972-36-NL   Belgium;Czech Republic;Denmark;France;Germany;Greece;Hungary;Italy;Netherlands;Poland;Portugal;Spain;Sweden;United Kingdom
      2008   Phase 3   EUCTR2007-001972-36-HU   Belgium;Czech Republic;Denmark;France;Germany;Greece;Hungary;Italy;Netherlands;Poland;Portugal;Spain;Sweden;United Kingdom
      2008   Phase 3   EUCTR2007-001972-36-GR   Belgium;Czech Republic;Denmark;France;Germany;Greece;Hungary;Italy;Netherlands;Poland;Portugal;Spain;Sweden;United Kingdom
      2008   Phase 3   EUCTR2007-001972-36-FR   Belgium;Czech Republic;Denmark;France;Germany;Greece;Hungary;Italy;Netherlands;Poland;Portugal;Spain;Sweden;United Kingdom
      2008   -   EUCTR2007-001972-36-DK   Belgium;Czech Republic;Denmark;France;Germany;Greece;Hungary;Italy;Netherlands;Poland;Portugal;Spain;Sweden;United Kingdom
      2008   Phase 3   EUCTR2007-001972-36-DE   Belgium;Czech Republic;Denmark;France;Germany;Greece;Hungary;Italy;Netherlands;Poland;Portugal;Spain;Sweden;United Kingdom
      2008   Phase 3   EUCTR2007-001972-36-BE   Belgium;Czech Republic;Denmark;France;Germany;Greece;Hungary;Italy;Netherlands;Poland;Portugal;Spain;Sweden;United Kingdom
      2007   Phase 3   EUCTR2007-001972-36-CZ   Belgium;Czech Republic;Denmark;France;Germany;Greece;Hungary;Italy;Netherlands;Poland;Portugal;Spain;Sweden;United Kingdom
D-phenylalanyl-L-H
   Novartis Pharma Services AG
      2009   Phase 3   EUCTR2007-001972-36-GB   Belgium;Czech Republic;Denmark;France;Germany;Greece;Hungary;Italy;Netherlands;Poland;Portugal;Spain;Sweden;United Kingdom
D-phenylalanyl-L-HE
   Novartis Pharma Services AG
      2008   Phase 3   EUCTR2007-001972-36-DE   Belgium;Czech Republic;Denmark;France;Germany;Greece;Hungary;Italy;Netherlands;Poland;Portugal;Spain;Sweden;United Kingdom
D-phenylalanyl-L-hemicystyl-L-phenylalanyl-D-trypto
   Novartis Farmacéutica, S. A
      2008   Phase 3   EUCTR2007-001972-36-ES   Belgium;Czech Republic;Denmark;France;Germany;Greece;Hungary;Italy;Netherlands;Poland;Portugal;Spain;Sweden;United Kingdom
D-phenylalanyl-L-hemicystyl-L-phenylalanyl-D-tryptophan
   Novartis Pharma Services AG
      2008   Phase 3   EUCTR2007-001972-36-PL   Belgium;Czech Republic;Denmark;France;Germany;Greece;Hungary;Italy;Netherlands;Poland;Portugal;Spain;Sweden;United Kingdom
D-phenylalanyl-L-hemicystyl-L-phenylalanyl-D-tryptophyl-L-lysyl-L-threonyl-L-hemiscystyl-L-threonino
   Novartis Farmacéutica, S.A.
      2010   Phase 3   EUCTR2009-016722-13-ES   Belgium;France;Germany;Italy;Norway;Poland;Spain;United Kingdom
   Novartis Pharma Services AG
      2012   Phase 3   EUCTR2009-016722-13-GB   Argentina;Belgium;Brazil;France;Germany;Israel;Italy;Mexico;Norway;Poland;Spain;United Kingdom;United States
      2011   Phase 3   EUCTR2009-016722-13-PL   Argentina;Belgium;Brazil;France;Germany;Israel;Italy;Mexico;Norway;Poland;Spain;United Kingdom;United States
      2011   Phase 3   EUCTR2009-016722-13-NO   Belgium;France;Germany;Italy;Norway;Poland;Spain;United Kingdom
      2010   Phase 3   EUCTR2009-016722-13-FR   Belgium;France;Germany;Italy;Norway;Poland;Spain;United Kingdom
      2010   Phase 3   EUCTR2009-016722-13-DE   Argentina;Belgium;Brazil;France;Germany;Israel;Italy;Mexico;Norway;Poland;Spain;United Kingdom;United States
      2010   Phase 3   EUCTR2009-016722-13-BE   Argentina;Belgium;Brazil;France;Germany;Israel;Italy;Mexico;Norway;Poland;Spain;United Kingdom;United States
      2009   -   EUCTR2007-001972-36-PT   Belgium;Czech Republic;Denmark;France;Germany;Greece;Hungary;Italy;Netherlands;Poland;Portugal;Spain;Sweden;United Kingdom
      2009   Phase 3   EUCTR2007-001972-36-GB   Belgium;Czech Republic;Denmark;France;Germany;Greece;Hungary;Italy;Netherlands;Poland;Portugal;Spain;Sweden;United Kingdom
      2008   Phase 3   EUCTR2007-001972-36-SE   Belgium;Czech Republic;Denmark;France;Germany;Greece;Hungary;Italy;Netherlands;Poland;Portugal;Spain;Sweden;United Kingdom
      2008   Phase 3   EUCTR2007-001972-36-NL   Belgium;Czech Republic;Denmark;France;Germany;Greece;Hungary;Italy;Netherlands;Poland;Portugal;Spain;Sweden;United Kingdom
      2008   Phase 3   EUCTR2007-001972-36-HU   Belgium;Czech Republic;Denmark;France;Germany;Greece;Hungary;Italy;Netherlands;Poland;Portugal;Spain;Sweden;United Kingdom
      2008   Phase 3   EUCTR2007-001972-36-GR   Belgium;Czech Republic;Denmark;France;Germany;Greece;Hungary;Italy;Netherlands;Poland;Portugal;Spain;Sweden;United Kingdom
      2008   Phase 3   EUCTR2007-001972-36-FR   Belgium;Czech Republic;Denmark;France;Germany;Greece;Hungary;Italy;Netherlands;Poland;Portugal;Spain;Sweden;United Kingdom
      2008   -   EUCTR2007-001972-36-DK   Belgium;Czech Republic;Denmark;France;Germany;Greece;Hungary;Italy;Netherlands;Poland;Portugal;Spain;Sweden;United Kingdom
      2008   Phase 3   EUCTR2007-001972-36-DE   Belgium;Czech Republic;Denmark;France;Germany;Greece;Hungary;Italy;Netherlands;Poland;Portugal;Spain;Sweden;United Kingdom
      2008   Phase 3   EUCTR2007-001972-36-BE   Belgium;Czech Republic;Denmark;France;Germany;Greece;Hungary;Italy;Netherlands;Poland;Portugal;Spain;Sweden;United Kingdom
      2007   Phase 3   EUCTR2007-001972-36-CZ   Belgium;Czech Republic;Denmark;France;Germany;Greece;Hungary;Italy;Netherlands;Poland;Portugal;Spain;Sweden;United Kingdom
Debio 4126
   Debiopharm International SA
      2025   Phase 3   NCT06930625   United States
      2022   Phase 1   NCT05364944   Denmark;France;Germany;Hungary;Israel;Italy;Poland;Portugal;Russian Federation;Spain;Sweden;United Kingdom
Denosumab
   Ruijin Hospital, Shanghai Jiao Tong University School of Medicine
      2024   -   ChiCTR2400091528   China
DG3173
   Aspireo Pharmaceuticals Limited
      2013   Phase 2   NCT02217800   -
      2012   Phase 2   NCT02235987   -
Direct surgery FOR acromegaly
   St. Olavs Hospital
      1999   Phase 4   NCT00521300   Norway
Dopamine
   Huiwen Tan, Zhiyong Chen
      2017   -   ChiCTR-OOC-17013525   -
Dopastatin
   Beaufour Ipsen Pharma
      2008   -   EUCTR2008-000500-83-LV   Belgium;Italy;Latvia;Lithuania
   Ipsen Pharma
      2008   -   EUCTR2008-000500-83-LT   Belgium;Italy;Latvia;Lithuania
   Ipsen Pharma SAS
      2008   -   EUCTR2008-000500-83-BE   Belgium;Italy;Latvia;Lithuania
Dostinex
   Novartis Pharma Services AG
      2008   -   EUCTR2005-005852-42-PT   Italy;Portugal
      2007   Phase 4   EUCTR2005-005852-42-BE   Belgium;Italy;Portugal
   Österreichisches Akromegalie Register
      2014   -   EUCTR2010-023674-39-AT   Austria
Dostinex 0,5 MG tabletten
   Novartis Pharma GmbH
      2006   -   EUCTR2005-002919-24-DE   Germany
Dostinex 0.5MG tabletts
   Department of Internal Medicine of the University of Munich
      2007   -   EUCTR2007-005585-12-DE   Germany
Dostinex 2CPR 0,5MG
   NOVARTIS FARMA
      2007   -   EUCTR2005-005852-42-IT   Italy;Portugal
Empagliflozin
   Huashan Hospital
      2020   -   NCT04520646   China
Escitalopram 10 MG
   Max-Planck-Institut für Psychiatrie
      2018   Phase 4   EUCTR2014-000265-43-DE   Germany
Escitalopram hexal 10 MG
   Max-Planck-Institut für Psychiatrie
      2018   Phase 4   EUCTR2014-000265-43-DE   Germany
Evista 60MG FILM-coated tablets
   Christie Hospital NHS Trust
      2007   Phase 4   EUCTR2006-004989-14-GB   United Kingdom
Furosemide
   Assistance Publique - Hôpitaux de Paris
      2007   -   NCT00531908   France
Gadolinium
   Assistance Publique - Hôpitaux de Paris
      2014   -   NCT02948322   France
Gamma knife radiosurgery
   Department of Endocrinology, Second Affiliated Hospital of Army Medical University
      2019   -   ChiCTR1800017714   China
   Samsung Medical Center
      2018   Phase 3   NCT03439709   Korea, Republic of
Genotropin
   University of Aarhus
      2012   -   NCT01723748   Denmark
GHR-LRX
   Ionis Pharmaceuticals, Inc.
      2021   Phase 2   NCT04522180   Estonia;Hungary;Italy;Latvia;Lithuania;Poland;Romania;Russian Federation;Serbia;United States
Glucose
   183 Xinqiao Zhengjie, Shapingba District, Chongqing
      2022   Phase 0   ChiCTR2300070856   China
   Assistance Publique - Hôpitaux de Paris
      2019   -   NCT04066569   France
Growth hormone
   183 Xinqiao Zhengjie, Shapingba District, Chongqing
      2022   Phase 0   ChiCTR2300070856   China
Growth hormone receptor antagonist
   Clinic of University of Wuerzburg
      2006   Phase 4   EUCTR2006-001108-35-DE   Germany
H01C B03
   CHIASMA INC.
      2016   Phase 3   EUCTR2015-002854-11-IT   Austria;Hungary;Italy;Lithuania;Poland;Spain;United States
Home administration
   Ipsen
      2007   Phase 3   NCT00447499   United States
Implante DE octreótida
   Indevus Pharmaceuticals Incorporated
      2009   -   EUCTR2008-003327-23-ES   Czech Republic;Hungary;Poland;Spain
Insulin
   183 Xinqiao Zhengjie, Shapingba District, Chongqing
      2022   Phase 0   ChiCTR2300070856   China
   Novartis Pharmaceuticals
      2014   Phase 4   NCT02060383   Belgium;Brazil;China;Denmark;Germany;India;Peru;Poland;Russian Federation;Thailand;Turkey;United States
Ionis GHR-LRX
   Ionis Pharmaceuticals, Inc.
      2019   Phase 2   NCT03967249   Hungary;Lithuania;Poland;Romania;Russian Federation;Serbia;United States
Ionis-GHR-LRX
   Ionis Pharmaceuticals, Inc.
      2018   Phase 2   NCT03548415   Austria;Czechia;Hungary;Lithuania;Poland;Romania;Russian Federation;Serbia;United States
Ipstyl
   BEAUFOUR IPSEN PHARMA
      2008   -   EUCTR2007-000155-34-IT   Belgium;Czech Republic;Finland;France;Germany;Italy;Netherlands;Spain;Sweden;United Kingdom
      2007   -   EUCTR2006-000297-72-IT   Czech Republic;Germany;Greece;Italy;Sweden;United Kingdom
   NOVARTIS FARMA
      2010   Phase 3   EUCTR2009-016722-13-IT   Belgium;France;Germany;Italy;Norway;Poland;Spain;United Kingdom
Ipstyl - 60 MG soluzione iniettabile PER USO sottocutaneo 1 siringa preriempita
   CHIASMA INC.
      2016   Phase 3   EUCTR2015-002854-11-IT   Austria;Hungary;Italy;Lithuania;Poland;Spain;United States
Ipstyl - 90 MG soluzione iniettabile PER USO sottocutaneo 1 siringa preriempita
   CHIASMA INC.
      2016   Phase 3   EUCTR2015-002854-11-IT   Austria;Hungary;Italy;Lithuania;Poland;Spain;United States
Ipstyl 120 MG
   AZIENDA OSPEDALIERA Spedali Civili di Brescia
      2013   -   EUCTR2012-005313-39-IT   Italy
Ipstyl 90 MG
   AZIENDA OSPEDALIERA Spedali Civili di Brescia
      2013   -   EUCTR2012-005313-39-IT   Italy
Ipstyl autogel
   Aarhus University Hospital, Department M
      2008   -   EUCTR2007-005244-25-DK   Denmark
   Novartis Pharma Services AG
      2011   Phase 3   EUCTR2009-016722-13-NO   Belgium;France;Germany;Italy;Norway;Poland;Spain;United Kingdom
Isis 766720
   IONIS PHARMACEUTICALS, INC.
      2020   Phase 2   EUCTR2020-000675-20-IT   Estonia;Hungary;Italy;Latvia;Lithuania;Poland;Romania;Russian Federation;Serbia;United States
   Ionis Pharmaceuticals, Inc.
      2021   Phase 2   EUCTR2020-000675-20-RO   Estonia;Hungary;Italy;Latvia;Lithuania;Poland;Romania;Russian Federation;Serbia;United States
      2020   Phase 2   EUCTR2020-000675-20-PL   Estonia;Hungary;Italy;Latvia;Lithuania;Poland;Romania;Russian Federation;Serbia;United States
      2020   Phase 2   EUCTR2020-000675-20-LV   Estonia;Hungary;Italy;Latvia;Lithuania;Poland;Romania;Russian Federation;Serbia;United States
      2020   Phase 2   EUCTR2020-000675-20-LT   Estonia;Hungary;Italy;Latvia;Lithuania;Poland;Romania;Russian Federation;Serbia;United States
      2020   Phase 2   EUCTR2020-000675-20-HU   Estonia;Hungary;Italy;Latvia;Lithuania;Poland;Romania;Russian Federation;Serbia;United States
      2019   Phase 2   EUCTR2019-000591-42-PL   Hungary;Lithuania;Poland;Romania;Russian Federation;Serbia;United States
      2019   Phase 2   EUCTR2019-000591-42-LT   Hungary;Lithuania;Poland;Romania;Russian Federation;Serbia;United States
      2019   Phase 2   EUCTR2019-000591-42-HU   Austria;Czech Republic;Hungary;Lithuania;Poland;Romania;Russian Federation;Serbia;United States
      2019   Phase 2   EUCTR2017-004259-22-RO   Austria;Czech Republic;Czechia;Hungary;Lithuania;Poland;Romania;Russian Federation;Serbia;United States
      2019   Phase 2   EUCTR2017-004259-22-PL   Austria;Czech Republic;Hungary;Lithuania;Poland;Romania;Russian Federation;Serbia;United States
      2018   Phase 2   EUCTR2017-004259-22-LT   Austria;Czech Republic;Hungary;Lithuania;Poland;Romania;Russian Federation;Serbia;United States
      2018   Phase 2   EUCTR2017-004259-22-HU   Austria;Czech Republic;Hungary;Lithuania;Poland;Romania;Russian Federation;Serbia;United States
      2018   Phase 2   EUCTR2017-004259-22-CZ   Austria;Czech Republic;Hungary;Lithuania;Poland;Romania;Russian Federation;Serbia;United States
      2018   Phase 2   EUCTR2017-004259-22-AT   Austria;Czech Republic;Hungary;Lithuania;Poland;Romania;Russian Federation;Serbia;United States
IT IS A chimera OF A dopamin 2 and AN somatostatin 2 receptor agonist
   Ipsen Pharma SAS
      2017   Phase 2   EUCTR2015-003868-37-BG   Belarus;Belgium;Bulgaria;Hungary;Serbia;Ukraine
      2016   Phase 2   EUCTR2015-003868-37-HU   Belarus;Belgium;Bulgaria;Hungary;Serbia;Ukraine
      2016   Phase 2   EUCTR2015-003868-37-BE   Belarus;Belgium;Bulgaria;Hungary;Serbia;Ukraine
ITF2984 1000 MCG
   Italfarmaco
      2014   Phase 2   NCT02111044   Czech Republic;France;Hungary;Italy;Netherlands;Poland;Romania;Serbia;Spain
ITF2984 2000 MCG
   Italfarmaco
      2014   Phase 2   NCT02111044   Czech Republic;France;Hungary;Italy;Netherlands;Poland;Romania;Serbia;Spain
ITF2984 500 MCG
   Italfarmaco
      2014   Phase 2   NCT02111044   Czech Republic;France;Hungary;Italy;Netherlands;Poland;Romania;Serbia;Spain
ITF2984 diacetate
   ITALFARMACO S.p.A.
      2014   Phase 2   EUCTR2013-003183-31-RO   Czech Republic;France;Hungary;Italy;Netherlands;Poland;Romania;Spain
      2014   Phase 2   EUCTR2013-003183-31-PL   Czech Republic;France;Hungary;Italy;Netherlands;Poland;Romania;Serbia;Spain
      2014   Phase 2   EUCTR2013-003183-31-NL   Czech Republic;France;Hungary;Italy;Netherlands;Poland;Romania;Serbia;Spain
      2014   Phase 2   EUCTR2013-003183-31-IT   Czech Republic;France;Hungary;Italy;Netherlands;Poland;Romania;Spain
      2014   Phase 2   EUCTR2013-003183-31-HU   Czech Republic;France;Hungary;Italy;Netherlands;Poland;Romania;Serbia;Spain
      2014   Phase 2   EUCTR2013-003183-31-FR   Czech Republic;France;Hungary;Italy;Netherlands;Poland;Romania;Spain
      2014   Phase 2   EUCTR2013-003183-31-ES   Czech Republic;France;Hungary;Italy;Netherlands;Poland;Romania;Spain
      2014   Phase 2   EUCTR2013-003183-31-CZ   Czech Republic;France;Hungary;Italy;Netherlands;Poland;Romania;Serbia;Spain
Ketogenic diet
   Erasmus Medical Center
      2023   -   NCT06949891   Netherlands
Lanreotida autogel 120 MG
   Beaufour Ipsen Pharma
      2008   -   EUCTR2007-000155-34-ES   Belgium;Czech Republic;Finland;France;Germany;Italy;Netherlands;Spain;Sweden;United Kingdom
Lanreotide
   BEAUFOUR IPSEN PHARMA
      2008   -   EUCTR2007-000155-34-IT   Belgium;Czech Republic;Finland;France;Germany;Italy;Netherlands;Spain;Sweden;United Kingdom
      2007   -   EUCTR2006-000297-72-IT   Czech Republic;Germany;Greece;Italy;Sweden;United Kingdom
   CHIASMA INC.
      2016   Phase 3   EUCTR2015-002854-11-IT   Austria;Hungary;Italy;Lithuania;Poland;Spain;United States
   Cedars-Sinai Medical Center
      2012   -   NCT01538966   United States
   Chiasma, Inc.
      2016   Phase 3   NCT02685709   Austria;France;Germany;Hungary;Italy;Lithuania;Poland;Romania;Russian Federation;Serbia;Spain;United Kingdom;United States
      2016   Phase 3   EUCTR2015-002854-11-RO   Austria;Canada;France;Germany;Hungary;Italy;Lithuania;Netherlands;Poland;Romania;Russian Federation;Serbia;Spain;United Kingdom;United States
      2016   Phase 3   EUCTR2015-002854-11-PL   Austria;Canada;France;Germany;Hungary;Italy;Lithuania;Netherlands;Poland;Romania;Russian Federation;Serbia;Spain;United Kingdom;United States
      2016   Phase 3   EUCTR2015-002854-11-NL   Austria;Canada;France;Germany;Hungary;Italy;Lithuania;Netherlands;Poland;Romania;Russian Federation;Serbia;Spain;United Kingdom;United States
      2016   Phase 3   EUCTR2015-002854-11-LT   Austria;France;Germany;Hungary;Italy;Lithuania;Netherlands;Poland;Romania;Russian Federation;Serbia;Spain;United Kingdom;United States
      2016   Phase 3   EUCTR2015-002854-11-HU   Austria;France;Germany;Hungary;Italy;Lithuania;Netherlands;Poland;Romania;Russian Federation;Serbia;Spain;United Kingdom;United States
      2016   Phase 3   EUCTR2015-002854-11-ES   Austria;Canada;France;Germany;Hungary;Italy;Lithuania;Netherlands;Poland;Romania;Russian Federation;Serbia;Spain;United Kingdom;United States
      2016   Phase 3   EUCTR2015-002854-11-DE   Austria;Canada;France;Germany;Hungary;Italy;Lithuania;Netherlands;Poland;Romania;Russian Federation;Serbia;Spain;United Kingdom;United States
      2016   Phase 3   EUCTR2015-002854-11-AT   Austria;France;Germany;Hungary;Italy;Lithuania;Netherlands;Poland;Romania;Russian Federation;Serbia;Spain;United Kingdom;United States
   Ipsen
      2014   -   NCT02020499   Australia
      2008   Phase 2   NCT00517491   Mexico
      2006   Phase 3   NCT00383708   Czech Republic;Czechia;Denmark;France;Germany;Greece;Italy;Netherlands;Spain;Sweden;United Kingdom
      2004   Phase 4   NCT00216398   Australia
      2004   Phase 4   NCT00149188   United Kingdom
      2000   Phase 2/Phase 3   NCT00234572   Czech Republic;Czechia;France;Germany;Hong Kong;Hungary;Netherlands;United Kingdom;United States
      2000   Phase 3   NCT00210457   France;Switzerland
   John Wayne Cancer Institute
      2013   Phase 4   NCT01861717   United States
   NOVARTIS FARMA
      2010   Phase 3   EUCTR2009-016722-13-IT   Belgium;France;Germany;Italy;Norway;Poland;Spain;United Kingdom
   Plymouth Hospital NHS Trust, R&D dept
      2006   Phase 2   EUCTR2005-004300-36-GB   United Kingdom
   University of Aarhus
      2008   -   NCT00652379   Denmark
   Österreichisches Akromegalie Register
      2014   -   EUCTR2010-023674-39-AT   Austria
Lanreotide (autogel formulation), duration OF treatment 24-56 weeks, depending ON dose interval
   Ipsen
      2005   Phase 3   NCT00444873   Germany
Lanreotide (autogel formulation), duration OF treatment 46-48 weeks
   Ipsen
      2001   Phase 3   NCT00499993   Italy
Lanreotide 60MG solution FOR injection
   Samsung Medical Center
      2018   Phase 3   NCT03439709   Korea, Republic of
Lanreotide acetate
   AZIENDA OSPEDALIERA Spedali Civili di Brescia
      2013   -   EUCTR2012-005313-39-IT   Italy
   IPSEN PHARMA SAS
      2015   Phase 1;Phase 3   EUCTR2014-002389-62-IT   Belgium;Czech Republic;France;Germany;Hungary;Italy;Lithuania;Netherlands;Poland;Romania;Russian Federation;Spain;United Kingdom
   Ipsen
      2014   Phase 3   NCT02493517   China
      2007   Phase 3   NCT00447499   United States
   Ipsen Group
      2016   Phase 1;Phase 2   EUCTR2014-002389-62-LT   Belgium;Czech Republic;France;Germany;Hungary;Italy;Lithuania;Netherlands;Poland;Romania;Russian Federation;Spain;United Kingdom
      2016   Phase 1;Phase 2   EUCTR2014-002389-62-ES   Belgium;Czech Republic;France;Germany;Hungary;Italy;Lithuania;Netherlands;Poland;Romania;Russian Federation;Spain;United Kingdom
      2015   Phase 1;Phase 2   EUCTR2014-002389-62-NL   Belgium;Czech Republic;France;Germany;Hungary;Italy;Lithuania;Netherlands;Poland;Romania;Russian Federation;Spain;United Kingdom
      2015   Phase 1;Phase 2   EUCTR2014-002389-62-GB   Belgium;Czech Republic;France;Germany;Hungary;Italy;Lithuania;Netherlands;Poland;Romania;Russian Federation;Spain;United Kingdom
      2015   Phase 1;Phase 2   EUCTR2014-002389-62-DE   Belgium;Czech Republic;France;Germany;Hungary;Italy;Lithuania;Netherlands;Poland;Romania;Russian Federation;Spain;United Kingdom
      2015   Phase 1;Phase 2   EUCTR2014-002389-62-BE   Belgium;Czech Republic;France;Germany;Italy;Lithuania;Netherlands;Poland;Romania;Russian Federation;Spain;United Kingdom
   Ipsen Pharma
      2016   Phase 1;Phase 2   EUCTR2014-002389-62-PL   Belgium;Czech Republic;France;Germany;Hungary;Italy;Lithuania;Netherlands;Poland;Romania;Russian Federation;Spain;United Kingdom
   Ipsen Pharma SAS
      2016   Phase 1;Phase 2   EUCTR2014-002389-62-CZ   Belgium;Czech Republic;France;Germany;Hungary;Italy;Lithuania;Netherlands;Poland;Romania;Russian Federation;Spain;United Kingdom
   Medizinische Universität Wien, KIMIII, Abteilung für Endokrinologie und Stoffwechsel
      2014   -   EUCTR2013-004782-14-AT   Austria
Lanreotide acetato
   IPSEN PHARMA SAS
      2015   Phase 1;Phase 3   EUCTR2014-002389-62-IT   Belgium;Czech Republic;France;Germany;Hungary;Italy;Lithuania;Netherlands;Poland;Romania;Russian Federation;Spain;United Kingdom
Lanreotide ATG
   Novartis Farmacéutica, S.A.
      2010   Phase 3   EUCTR2009-016722-13-ES   Belgium;France;Germany;Italy;Norway;Poland;Spain;United Kingdom
   Novartis Pharma Services AG
      2011   Phase 3   EUCTR2009-016722-13-PL   Argentina;Belgium;Brazil;France;Germany;Israel;Italy;Mexico;Norway;Poland;Spain;United Kingdom;United States
      2011   Phase 3   EUCTR2009-016722-13-NO   Belgium;France;Germany;Italy;Norway;Poland;Spain;United Kingdom
      2010   Phase 3   EUCTR2009-016722-13-FR   Belgium;France;Germany;Italy;Norway;Poland;Spain;United Kingdom
      2010   Phase 3   EUCTR2009-016722-13-DE   Argentina;Belgium;Brazil;France;Germany;Israel;Italy;Mexico;Norway;Poland;Spain;United Kingdom;United States
      2010   Phase 3   EUCTR2009-016722-13-BE   Argentina;Belgium;Brazil;France;Germany;Israel;Italy;Mexico;Norway;Poland;Spain;United Kingdom;United States
Lanreotide ATG 120MG
   Novartis Pharmaceuticals
      2010   Phase 3   NCT01137682   Argentina;Belgium;Brazil;Canada;Colombia;France;Germany;Israel;Italy;Mexico;Norway;Poland;Romania;Russian Federation;Saudi Arabia;Spain;Turkey;United Kingdom;United States
Lanreotide autogel
   Fondazione Policlinico Universitario Agostino Gemelli IRCCS
      2023   -   NCT06607666   Italy
   Ipsen
      2014   Phase 3   NCT02493517   China
Lanreotide autogel 120 MG
   BEAUFOUR IPSEN Pharma
      2007   -   EUCTR2006-000297-72-SE   Czech Republic;Germany;Greece;Italy;Sweden;United Kingdom
      2007   Phase 3   EUCTR2006-000297-72-GR   Czech Republic;Denmark;Germany;Greece;Italy;Sweden;United Kingdom
      2007   Phase 3   EUCTR2006-000297-72-DK   Czech Republic;Denmark;Germany;Greece;Italy;Sweden;United Kingdom
      2007   -   EUCTR2006-000297-72-DE   Czech Republic;Germany;Greece;Italy;Sweden;United Kingdom
      2007   -   EUCTR2006-000297-72-CZ   Czech Republic;Germany;Greece;Italy;Sweden;United Kingdom
      2006   Phase 3   EUCTR2006-000297-72-GB   Czech Republic;Denmark;Germany;Greece;Italy;Sweden;United Kingdom
   Beaufour Ipsen Pharma
      2009   -   EUCTR2007-005838-37-GR   Denmark;Finland;France;Greece;Latvia;Netherlands;Sweden
      2008   -   EUCTR2007-005838-37-SE   Denmark;Finland;France;Greece;Latvia;Netherlands;Sweden
      2008   -   EUCTR2007-005838-37-NL   Denmark;Finland;France;Greece;Latvia;Netherlands;Sweden
      2008   Phase 4   EUCTR2007-005838-37-FR   Denmark;Finland;France;Greece;Latvia;Netherlands;Sweden
      2008   Phase 3   EUCTR2007-000155-34-NL   Belgium;Czech Republic;Finland;France;Germany;Italy;Netherlands;Spain;Sweden;United Kingdom
      2008   Phase 3   EUCTR2007-000155-34-FR   Belgium;Czech Republic;Finland;France;Germany;Italy;Netherlands;Spain;Sweden;United Kingdom
   Ipsen
      2008   Phase 4   NCT00701363   Brazil;Denmark;Finland;France;Greece;Korea, Republic of;Latvia;Netherlands;Norway;Poland;Romania;Russian Federation;Serbia;Sweden
      2008   Phase 3   NCT00690898   Belgium;Czech Republic;Czechia;Finland;France;Germany;Italy;Netherlands;Spain;Sweden;Turkey;United Kingdom
   Ipsen Pharma
      2008   -   EUCTR2007-005838-37-LV   Denmark;Finland;France;Greece;Latvia;Netherlands;Sweden
      2008   -   EUCTR2007-005838-37-FI   Denmark;Finland;France;Greece;Latvia;Netherlands;Sweden
      2008   -   EUCTR2007-005838-37-DK   Denmark;Finland;France;Greece;Latvia;Netherlands;Sweden
   Ipsen Pharma SAS
      2009   Phase 3   EUCTR2007-000155-34-GB   Belgium;Czech Republic;Finland;France;Germany;Italy;Netherlands;Spain;Sweden;United Kingdom
      2008   -   EUCTR2007-000155-34-SE   Belgium;Czech Republic;Finland;France;Germany;Italy;Netherlands;Spain;Sweden;United Kingdom
      2008   -   EUCTR2007-000155-34-FI   Belgium;Czech Republic;Finland;France;Germany;Italy;Netherlands;Spain;Sweden;United Kingdom
      2008   -   EUCTR2007-000155-34-DE   Belgium;Czech Republic;Finland;France;Germany;Italy;Netherlands;Spain;Sweden;United Kingdom
      2008   -   EUCTR2007-000155-34-CZ   Belgium;Czech Republic;Finland;France;Germany;Italy;Netherlands;Spain;Sweden;United Kingdom
      2008   Phase 3   EUCTR2007-000155-34-BE   Belgium;Czech Republic;Finland;France;Germany;Italy;Netherlands;Spain;Sweden;United Kingdom
Lanreotide autogel 120MG
   Beaufour Ipsen Pharma
      2008   -   EUCTR2007-005838-37-NL   Denmark;Finland;France;Greece;Latvia;Netherlands;Sweden
Lanreotide autogel and octreotide LAR
   Odense University Hospital
      2002   Phase 4   NCT00145405   Denmark
Lanreotide PRF
   IPSEN PHARMA SAS
      2015   Phase 1;Phase 3   EUCTR2014-002389-62-IT   Belgium;Czech Republic;France;Germany;Hungary;Italy;Lithuania;Netherlands;Poland;Romania;Russian Federation;Spain;United Kingdom
   Ipsen
      2015   Phase 1/Phase 2   NCT02396953   Belgium;Czech Republic;Czechia;France;Germany;Italy;Lithuania;Netherlands;Poland;Romania;Russian Federation;Spain;United Kingdom
   Ipsen Group
      2016   Phase 1;Phase 2   EUCTR2014-002389-62-LT   Belgium;Czech Republic;France;Germany;Hungary;Italy;Lithuania;Netherlands;Poland;Romania;Russian Federation;Spain;United Kingdom
      2016   Phase 1;Phase 2   EUCTR2014-002389-62-ES   Belgium;Czech Republic;France;Germany;Hungary;Italy;Lithuania;Netherlands;Poland;Romania;Russian Federation;Spain;United Kingdom
      2015   Phase 1;Phase 2   EUCTR2014-002389-62-NL   Belgium;Czech Republic;France;Germany;Hungary;Italy;Lithuania;Netherlands;Poland;Romania;Russian Federation;Spain;United Kingdom
      2015   Phase 1;Phase 2   EUCTR2014-002389-62-GB   Belgium;Czech Republic;France;Germany;Hungary;Italy;Lithuania;Netherlands;Poland;Romania;Russian Federation;Spain;United Kingdom
      2015   Phase 1;Phase 2   EUCTR2014-002389-62-DE   Belgium;Czech Republic;France;Germany;Hungary;Italy;Lithuania;Netherlands;Poland;Romania;Russian Federation;Spain;United Kingdom
      2015   Phase 1;Phase 2   EUCTR2014-002389-62-BE   Belgium;Czech Republic;France;Germany;Italy;Lithuania;Netherlands;Poland;Romania;Russian Federation;Spain;United Kingdom
   Ipsen Pharma
      2016   Phase 1;Phase 2   EUCTR2014-002389-62-PL   Belgium;Czech Republic;France;Germany;Hungary;Italy;Lithuania;Netherlands;Poland;Romania;Russian Federation;Spain;United Kingdom
   Ipsen Pharma SAS
      2016   Phase 1;Phase 2   EUCTR2014-002389-62-CZ   Belgium;Czech Republic;France;Germany;Hungary;Italy;Lithuania;Netherlands;Poland;Romania;Russian Federation;Spain;United Kingdom
Lanreotide-autogel 120 MG
   Federico II University
      2003   Phase 4   NCT00627796   Italy
Liraglutide
   Novartis Pharmaceuticals
      2014   Phase 4   NCT02060383   Belgium;Brazil;China;Denmark;Germany;India;Peru;Poland;Russian Federation;Thailand;Turkey;United States
Medical history, demographics
   Pfizer
      2004   Phase 4   NCT00151437   Canada
Medications FOR acromegaly
   Columbia University
      2003   -   NCT01809808   United States
Mediterranean diet
   Erasmus Medical Center
      2023   -   NCT06949891   Netherlands
Metformin
   Department of Endocrinology, Second Affiliated Hospital of Army Medical University
      2019   -   ChiCTR1800017714   China
   Novartis Pharmaceuticals
      2014   Phase 4   NCT02060383   Belgium;Brazil;China;Denmark;Germany;India;Peru;Poland;Russian Federation;Thailand;Turkey;United States
Mycapssa
   CHIASMA INC.
      2017   Phase 3   EUCTR2017-000737-31-IT   Canada;Denmark;Germany;Hungary;Israel;Italy;Netherlands;Poland;Romania;Sweden;Turkey;United Kingdom;United States
      2016   Phase 3   EUCTR2015-002854-11-IT   Austria;Hungary;Italy;Lithuania;Poland;Spain;United States
   Chiasma, Inc.
      2018   Phase 3   EUCTR2017-000737-31-SI   Bulgaria;Canada;Denmark;Germany;Hungary;Israel;Italy;Latvia;Netherlands;Poland;Romania;Slovenia;Sweden;Turkey;United Kingdom;United States
      2018   Phase 3   EUCTR2017-000737-31-NL   Bulgaria;Canada;Denmark;Germany;Hungary;Israel;Italy;Latvia;Netherlands;Poland;Romania;Slovenia;Sweden;Turkey;United Kingdom;United States
      2018   Phase 3   EUCTR2017-000737-31-LV   Belgium;Bulgaria;Canada;Denmark;Germany;Hungary;Israel;Italy;Latvia;Netherlands;Poland;Romania;Slovenia;Sweden;Turkey;United Kingdom;United States
      2018   Phase 3   EUCTR2017-000737-31-BG   Belgium;Bulgaria;Canada;Denmark;Germany;Hungary;Israel;Italy;Latvia;Netherlands;Poland;Romania;Slovenia;Sweden;Turkey;United Kingdom;United States
      2017   Phase 3   EUCTR2017-000737-31-SE   Bulgaria;Canada;Denmark;Germany;Hungary;Israel;Italy;Latvia;Netherlands;Poland;Romania;Slovenia;Sweden;Turkey;United Kingdom;United States
      2017   Phase 3   EUCTR2017-000737-31-PL   Bulgaria;Canada;Denmark;Germany;Hungary;Israel;Italy;Latvia;Netherlands;Poland;Romania;Slovenia;Sweden;Turkey;United Kingdom;United States
      2017   Phase 3   EUCTR2017-000737-31-HU   Bulgaria;Canada;Denmark;Germany;Hungary;Israel;Italy;Latvia;Netherlands;Poland;Romania;Slovenia;Sweden;Turkey;United Kingdom;United States
      2017   Phase 3   EUCTR2017-000737-31-GB   Bulgaria;Canada;Denmark;Germany;Hungary;Israel;Italy;Latvia;Netherlands;Poland;Romania;Slovenia;Sweden;Turkey;United Kingdom;United States
      2017   Phase 3   EUCTR2017-000737-31-DK   Bulgaria;Canada;Denmark;Germany;Hungary;Israel;Italy;Latvia;Netherlands;Poland;Romania;Slovenia;Sweden;Turkey;United Kingdom;United States
      2017   Phase 3   EUCTR2017-000737-31-DE   Bulgaria;Canada;Denmark;Germany;Hungary;Israel;Italy;Latvia;Netherlands;Poland;Romania;Slovenia;Sweden;Turkey;United Kingdom;United States
      2016   Phase 3   EUCTR2015-002854-11-RO   Austria;Canada;France;Germany;Hungary;Italy;Lithuania;Netherlands;Poland;Romania;Russian Federation;Serbia;Spain;United Kingdom;United States
      2016   Phase 3   EUCTR2015-002854-11-PL   Austria;Canada;France;Germany;Hungary;Italy;Lithuania;Netherlands;Poland;Romania;Russian Federation;Serbia;Spain;United Kingdom;United States
      2016   Phase 3   EUCTR2015-002854-11-NL   Austria;Canada;France;Germany;Hungary;Italy;Lithuania;Netherlands;Poland;Romania;Russian Federation;Serbia;Spain;United Kingdom;United States
      2016   Phase 3   EUCTR2015-002854-11-LT   Austria;France;Germany;Hungary;Italy;Lithuania;Netherlands;Poland;Romania;Russian Federation;Serbia;Spain;United Kingdom;United States
      2016   Phase 3   EUCTR2015-002854-11-HU   Austria;France;Germany;Hungary;Italy;Lithuania;Netherlands;Poland;Romania;Russian Federation;Serbia;Spain;United Kingdom;United States
      2016   Phase 3   EUCTR2015-002854-11-ES   Austria;Canada;France;Germany;Hungary;Italy;Lithuania;Netherlands;Poland;Romania;Russian Federation;Serbia;Spain;United Kingdom;United States
      2016   Phase 3   EUCTR2015-002854-11-DE   Austria;Canada;France;Germany;Hungary;Italy;Lithuania;Netherlands;Poland;Romania;Russian Federation;Serbia;Spain;United Kingdom;United States
      2016   Phase 3   EUCTR2015-002854-11-AT   Austria;France;Germany;Hungary;Italy;Lithuania;Netherlands;Poland;Romania;Russian Federation;Serbia;Spain;United Kingdom;United States
Octreolin
   CHIASMA INC.
      2015   Phase 3   EUCTR2015-001292-51-IT   Germany;Hungary;Israel;Italy;Lithuania;Netherlands;Poland;Romania;Serbia;Slovakia;Slovenia;United Kingdom
   CHIASMA, INC.
      2011   -   EUCTR2011-002912-10-IT   Brazil;Canada;Germany;Hungary;Israel;Italy;Lithuania;Mexico;Netherlands;Poland;Slovakia;Slovenia;United Kingdom;United States
   Chiasma, Inc
      2011   Phase 3   EUCTR2011-002912-10-GB   Germany;Hungary;Israel;Italy;Lithuania;Mexico;Netherlands;Poland;Romania;Slovakia;Slovenia;United Kingdom
   Chiasma, Inc.
      2015   -   EUCTR2015-001292-51-SI   Germany;Hungary;Israel;Italy;Lithuania;Netherlands;Poland;Romania;Serbia;Slovakia;Slovenia;United Kingdom
      2015   Phase 3   EUCTR2015-001292-51-PL   Germany;Hungary;Israel;Italy;Lithuania;Netherlands;Poland;Romania;Serbia;Slovakia;Slovenia;United Kingdom
      2015   -   EUCTR2015-001292-51-HU   Germany;Hungary;Israel;Italy;Lithuania;Netherlands;Poland;Romania;Serbia;Slovakia;Slovenia;United Kingdom
      2015   Phase 3   EUCTR2015-001292-51-DE   Germany;Hungary;Israel;Italy;Lithuania;Netherlands;Poland;Romania;Serbia;Slovakia;Slovenia;United Kingdom
      2012   -   EUCTR2011-002912-10-SI   Germany;Hungary;Israel;Italy;Lithuania;Mexico;Netherlands;Poland;Romania;Serbia;Slovakia;Slovenia;United Kingdom;United States
      2012   -   EUCTR2011-002912-10-PL   Germany;Hungary;Israel;Italy;Lithuania;Mexico;Netherlands;Poland;Romania;Serbia;Slovakia;Slovenia;United Kingdom
      2012   -   EUCTR2011-002912-10-NL   Germany;Hungary;Israel;Italy;Lithuania;Mexico;Netherlands;Poland;Romania;Serbia;Slovakia;Slovenia;United Kingdom
      2012   -   EUCTR2011-002912-10-LT   Germany;Hungary;Israel;Italy;Lithuania;Mexico;Netherlands;Poland;Romania;Serbia;Slovakia;Slovenia;United Kingdom
      2011   -   EUCTR2011-002912-10-SK   Germany;Hungary;Israel;Italy;Lithuania;Mexico;Netherlands;Poland;Romania;Serbia;Slovakia;Slovenia;United Kingdom;United States
      2011   -   EUCTR2011-002912-10-HU   Germany;Hungary;Israel;Italy;Lithuania;Mexico;Netherlands;Poland;Romania;Serbia;Slovakia;Slovenia;United Kingdom
      2011   -   EUCTR2011-002912-10-DE   Germany;Hungary;Israel;Italy;Lithuania;Mexico;Netherlands;Poland;Romania;Serbia;Slovakia;Slovenia;United Kingdom
Octreotid
   Novartis Pharma GmbH
      2006   -   EUCTR2005-002919-24-DE   Germany
Octreotida
   Novartis Farmacéutica, S. A
      2008   Phase 3   EUCTR2007-001972-36-ES   Belgium;Czech Republic;Denmark;France;Germany;Greece;Hungary;Italy;Netherlands;Poland;Portugal;Spain;Sweden;United Kingdom
Octreotida acetato
   Indevus Pharmaceuticals Incorporated
      2009   -   EUCTR2008-003327-23-ES   Czech Republic;Hungary;Poland;Spain
Octreotidacetat
   Department of Internal Medicine of the University of Munich
      2007   -   EUCTR2007-005585-12-DE   Germany
Octreotide
   Aspireo Pharmaceuticals Limited
      2013   Phase 2   NCT02217800   -
      2012   Phase 2   NCT02235987   -
   Camurus AB
      2020   Phase 3   EUCTR2019-002190-66-IT   Bulgaria;Germany;Greece;Hungary;Italy;Poland;Russian Federation;Spain;Sweden;Turkey;United Kingdom;United States
      2020   Phase 3   EUCTR2019-001191-11-IT   Bulgaria;Germany;Greece;Hungary;Italy;Netherlands;Poland;Russian Federation;Spain;Sweden;Turkey;United Kingdom;United States
      2019   Phase 3   NCT04125836   Germany;Greece;Hungary;Italy;Poland;Russian Federation;Serbia;Spain;Turkey;United Kingdom;United States
      2019   Phase 3   NCT04076462   Germany;Greece;Hungary;Italy;Poland;Russian Federation;Spain;Turkey;United Kingdom;United States
   Endo Pharmaceuticals
      2011   Phase 3   NCT01295060   United States
   ITALFARMACO S.p.A.
      2014   Phase 2   EUCTR2013-003183-31-NL   Czech Republic;France;Hungary;Italy;Netherlands;Poland;Romania;Serbia;Spain
      2014   Phase 2   EUCTR2013-003183-31-FR   Czech Republic;France;Hungary;Italy;Netherlands;Poland;Romania;Spain
      2014   Phase 2   EUCTR2013-003183-31-ES   Czech Republic;France;Hungary;Italy;Netherlands;Poland;Romania;Spain
   Indevus Pharmaceuticals Incorporated
      2009   -   EUCTR2008-003327-23-ES   Czech Republic;Hungary;Poland;Spain
   Italfarmaco
      2014   Phase 2   NCT02111044   Czech Republic;France;Hungary;Italy;Netherlands;Poland;Romania;Serbia;Spain
   NOVARTIS FARMA
      2010   Phase 3   EUCTR2009-016722-13-IT   Belgium;France;Germany;Italy;Norway;Poland;Spain;United Kingdom
      2008   -   EUCTR2007-001972-36-IT   Belgium;Czech Republic;Denmark;France;Germany;Greece;Hungary;Italy;Netherlands;Poland;Portugal;Spain;Sweden;United Kingdom
      2007   -   EUCTR2005-005852-42-IT   Italy;Portugal
   NOVARTIS FARMA S.P.A.
      2016   Phase 3   EUCTR2014-002630-31-IT   Argentina;Belgium;Brazil;Bulgaria;China;Colombia;France;Germany;Hungary;Italy;Mexico;Portugal;Sweden;Turkey;United Kingdom;Venezuela, Bolivarian Republic of
   Novartis Farmacéutica, S.A.
      2010   Phase 3   EUCTR2009-016722-13-ES   Belgium;France;Germany;Italy;Norway;Poland;Spain;United Kingdom
   Novartis Pharma Services AG
      2012   Phase 3   EUCTR2009-016722-13-GB   Argentina;Belgium;Brazil;France;Germany;Israel;Italy;Mexico;Norway;Poland;Spain;United Kingdom;United States
      2011   Phase 3   EUCTR2009-016722-13-PL   Argentina;Belgium;Brazil;France;Germany;Israel;Italy;Mexico;Norway;Poland;Spain;United Kingdom;United States
      2011   Phase 3   EUCTR2009-016722-13-NO   Belgium;France;Germany;Italy;Norway;Poland;Spain;United Kingdom
      2010   Phase 3   EUCTR2009-016722-13-FR   Belgium;France;Germany;Italy;Norway;Poland;Spain;United Kingdom
      2010   Phase 3   EUCTR2009-016722-13-DE   Argentina;Belgium;Brazil;France;Germany;Israel;Italy;Mexico;Norway;Poland;Spain;United Kingdom;United States
      2010   Phase 3   EUCTR2009-016722-13-BE   Argentina;Belgium;Brazil;France;Germany;Israel;Italy;Mexico;Norway;Poland;Spain;United Kingdom;United States
      2009   -   EUCTR2007-001972-36-PT   Belgium;Czech Republic;Denmark;France;Germany;Greece;Hungary;Italy;Netherlands;Poland;Portugal;Spain;Sweden;United Kingdom
      2009   Phase 3   EUCTR2007-001972-36-GB   Belgium;Czech Republic;Denmark;France;Germany;Greece;Hungary;Italy;Netherlands;Poland;Portugal;Spain;Sweden;United Kingdom
      2008   Phase 3   EUCTR2007-001972-36-SE   Belgium;Czech Republic;Denmark;France;Germany;Greece;Hungary;Italy;Netherlands;Poland;Portugal;Spain;Sweden;United Kingdom
      2008   Phase 3   EUCTR2007-001972-36-PL   Belgium;Czech Republic;Denmark;France;Germany;Greece;Hungary;Italy;Netherlands;Poland;Portugal;Spain;Sweden;United Kingdom
      2008   Phase 3   EUCTR2007-001972-36-NL   Belgium;Czech Republic;Denmark;France;Germany;Greece;Hungary;Italy;Netherlands;Poland;Portugal;Spain;Sweden;United Kingdom
      2008   Phase 3   EUCTR2007-001972-36-HU   Belgium;Czech Republic;Denmark;France;Germany;Greece;Hungary;Italy;Netherlands;Poland;Portugal;Spain;Sweden;United Kingdom
      2008   Phase 3   EUCTR2007-001972-36-GR   Belgium;Czech Republic;Denmark;France;Germany;Greece;Hungary;Italy;Netherlands;Poland;Portugal;Spain;Sweden;United Kingdom
      2008   Phase 3   EUCTR2007-001972-36-FR   Belgium;Czech Republic;Denmark;France;Germany;Greece;Hungary;Italy;Netherlands;Poland;Portugal;Spain;Sweden;United Kingdom
      2008   -   EUCTR2007-001972-36-DK   Belgium;Czech Republic;Denmark;France;Germany;Greece;Hungary;Italy;Netherlands;Poland;Portugal;Spain;Sweden;United Kingdom
      2008   Phase 3   EUCTR2007-001972-36-DE   Belgium;Czech Republic;Denmark;France;Germany;Greece;Hungary;Italy;Netherlands;Poland;Portugal;Spain;Sweden;United Kingdom
      2008   Phase 3   EUCTR2007-001972-36-BE   Belgium;Czech Republic;Denmark;France;Germany;Greece;Hungary;Italy;Netherlands;Poland;Portugal;Spain;Sweden;United Kingdom
      2008   -   EUCTR2005-005852-42-PT   Italy;Portugal
      2007   Phase 3   EUCTR2007-001972-36-CZ   Belgium;Czech Republic;Denmark;France;Germany;Greece;Hungary;Italy;Netherlands;Poland;Portugal;Spain;Sweden;United Kingdom
      2007   Phase 4   EUCTR2005-005852-42-BE   Belgium;Italy;Portugal
   Novartis Pharmaceuticals
      2008   Phase 3   NCT00600886   Argentina;Australia;Belgium;Brazil;Canada;China;Colombia;Czech Republic;Czechia;Denmark;France;Germany;Greece;Hungary;Israel;Italy;Korea, Republic of;Mexico;Netherlands;Norway;Poland;Portugal;Russian Federation;Spain;Sweden;Switzerland;Taiwan;Turkey;United Kingdom;United States;Venezuela
      2004   Phase 2   NCT00088582   Australia;Belgium;France;Germany;Italy;Netherlands;Spain;Switzerland;United Kingdom;United States
      2002   Phase 4   NCT00171886   Spain
   Ono Pharmaceutical Co. Ltd
      2018   Phase 1   NCT03571594   United States
   Oxford Radcliffe Hospitals NHS trust
      2006   Phase 4   EUCTR2005-003496-20-GB   United Kingdom
   St. Olavs Hospital
      1999   Phase 4   NCT00521300   Norway
   University of Aarhus
      2008   -   NCT00652379   Denmark
   Wada Jun
      2022   Phase 2   JPRN-jRCT2061220037   -
   Österreichisches Akromegalie Register
      2014   -   EUCTR2010-023674-39-AT   Austria
Octreotide acetate
   Ambrilia Biopharma Inc.
      2008   Phase 3   EUCTR2007-004320-21-SK   Hungary;Slovakia
      2007   -   EUCTR2007-004320-21-HU   Hungary
      2007   Phase 3   EUCTR2006-005855-14-SK   Hungary;Slovakia
      2007   -   EUCTR2006-005855-14-HU   Hungary
   Asan Medical Center
      2014   Phase 4   NCT02427295   Korea, Republic of
   CHIASMA INC.
      2016   Phase 3   EUCTR2015-002854-11-IT   Austria;Hungary;Italy;Lithuania;Poland;Spain;United States
      2015   Phase 3   EUCTR2015-001292-51-IT   Germany;Hungary;Israel;Italy;Lithuania;Netherlands;Poland;Romania;Serbia;Slovakia;Slovenia;United Kingdom
   CHIASMA, INC.
      2011   -   EUCTR2011-002912-10-IT   Brazil;Canada;Germany;Hungary;Israel;Italy;Lithuania;Mexico;Netherlands;Poland;Slovakia;Slovenia;United Kingdom;United States
   Camurus AB
      2014   -   EUCTR2013-000533-12-IT   Germany;Italy
      2014   Phase 2   EUCTR2013-000533-12-DE   Germany;Italy
   Chiasma, Inc
      2011   Phase 3   EUCTR2011-002912-10-GB   Germany;Hungary;Israel;Italy;Lithuania;Mexico;Netherlands;Poland;Romania;Slovakia;Slovenia;United Kingdom
   Chiasma, Inc.
      2018   Phase 3   EUCTR2017-000737-31-SI   Bulgaria;Canada;Denmark;Germany;Hungary;Israel;Italy;Latvia;Netherlands;Poland;Romania;Slovenia;Sweden;Turkey;United Kingdom;United States
      2018   Phase 3   EUCTR2017-000737-31-NL   Bulgaria;Canada;Denmark;Germany;Hungary;Israel;Italy;Latvia;Netherlands;Poland;Romania;Slovenia;Sweden;Turkey;United Kingdom;United States
      2018   Phase 3   EUCTR2017-000737-31-LV   Belgium;Bulgaria;Canada;Denmark;Germany;Hungary;Israel;Italy;Latvia;Netherlands;Poland;Romania;Slovenia;Sweden;Turkey;United Kingdom;United States
      2018   Phase 3   EUCTR2017-000737-31-BG   Belgium;Bulgaria;Canada;Denmark;Germany;Hungary;Israel;Italy;Latvia;Netherlands;Poland;Romania;Slovenia;Sweden;Turkey;United Kingdom;United States
      2017   Phase 3   EUCTR2017-000737-31-SE   Bulgaria;Canada;Denmark;Germany;Hungary;Israel;Italy;Latvia;Netherlands;Poland;Romania;Slovenia;Sweden;Turkey;United Kingdom;United States
      2017   Phase 3   EUCTR2017-000737-31-PL   Bulgaria;Canada;Denmark;Germany;Hungary;Israel;Italy;Latvia;Netherlands;Poland;Romania;Slovenia;Sweden;Turkey;United Kingdom;United States
      2017   Phase 3   EUCTR2017-000737-31-HU   Bulgaria;Canada;Denmark;Germany;Hungary;Israel;Italy;Latvia;Netherlands;Poland;Romania;Slovenia;Sweden;Turkey;United Kingdom;United States
      2017   Phase 3   EUCTR2017-000737-31-GB   Bulgaria;Canada;Denmark;Germany;Hungary;Israel;Italy;Latvia;Netherlands;Poland;Romania;Slovenia;Sweden;Turkey;United Kingdom;United States
      2017   Phase 3   EUCTR2017-000737-31-DK   Bulgaria;Canada;Denmark;Germany;Hungary;Israel;Italy;Latvia;Netherlands;Poland;Romania;Slovenia;Sweden;Turkey;United Kingdom;United States
      2017   Phase 3   EUCTR2017-000737-31-DE   Bulgaria;Canada;Denmark;Germany;Hungary;Israel;Italy;Latvia;Netherlands;Poland;Romania;Slovenia;Sweden;Turkey;United Kingdom;United States
      2016   Phase 3   EUCTR2015-002854-11-RO   Austria;Canada;France;Germany;Hungary;Italy;Lithuania;Netherlands;Poland;Romania;Russian Federation;Serbia;Spain;United Kingdom;United States
      2016   Phase 3   EUCTR2015-002854-11-PL   Austria;Canada;France;Germany;Hungary;Italy;Lithuania;Netherlands;Poland;Romania;Russian Federation;Serbia;Spain;United Kingdom;United States
      2016   Phase 3   EUCTR2015-002854-11-NL   Austria;Canada;France;Germany;Hungary;Italy;Lithuania;Netherlands;Poland;Romania;Russian Federation;Serbia;Spain;United Kingdom;United States
      2016   Phase 3   EUCTR2015-002854-11-LT   Austria;France;Germany;Hungary;Italy;Lithuania;Netherlands;Poland;Romania;Russian Federation;Serbia;Spain;United Kingdom;United States
      2016   Phase 3   EUCTR2015-002854-11-HU   Austria;France;Germany;Hungary;Italy;Lithuania;Netherlands;Poland;Romania;Russian Federation;Serbia;Spain;United Kingdom;United States
      2016   Phase 3   EUCTR2015-002854-11-ES   Austria;Canada;France;Germany;Hungary;Italy;Lithuania;Netherlands;Poland;Romania;Russian Federation;Serbia;Spain;United Kingdom;United States
      2016   Phase 3   EUCTR2015-002854-11-DE   Austria;Canada;France;Germany;Hungary;Italy;Lithuania;Netherlands;Poland;Romania;Russian Federation;Serbia;Spain;United Kingdom;United States
      2016   Phase 3   EUCTR2015-002854-11-AT   Austria;France;Germany;Hungary;Italy;Lithuania;Netherlands;Poland;Romania;Russian Federation;Serbia;Spain;United Kingdom;United States
      2015   -   EUCTR2015-001292-51-SI   Germany;Hungary;Israel;Italy;Lithuania;Netherlands;Poland;Romania;Serbia;Slovakia;Slovenia;United Kingdom
      2015   Phase 3   EUCTR2015-001292-51-PL   Germany;Hungary;Israel;Italy;Lithuania;Netherlands;Poland;Romania;Serbia;Slovakia;Slovenia;United Kingdom
      2015   -   EUCTR2015-001292-51-HU   Germany;Hungary;Israel;Italy;Lithuania;Netherlands;Poland;Romania;Serbia;Slovakia;Slovenia;United Kingdom
      2015   Phase 3   EUCTR2015-001292-51-DE   Germany;Hungary;Israel;Italy;Lithuania;Netherlands;Poland;Romania;Serbia;Slovakia;Slovenia;United Kingdom
      2012   -   EUCTR2011-002912-10-SI   Germany;Hungary;Israel;Italy;Lithuania;Mexico;Netherlands;Poland;Romania;Serbia;Slovakia;Slovenia;United Kingdom;United States
      2012   -   EUCTR2011-002912-10-PL   Germany;Hungary;Israel;Italy;Lithuania;Mexico;Netherlands;Poland;Romania;Serbia;Slovakia;Slovenia;United Kingdom
      2012   -   EUCTR2011-002912-10-NL   Germany;Hungary;Israel;Italy;Lithuania;Mexico;Netherlands;Poland;Romania;Serbia;Slovakia;Slovenia;United Kingdom
      2012   -   EUCTR2011-002912-10-LT   Germany;Hungary;Israel;Italy;Lithuania;Mexico;Netherlands;Poland;Romania;Serbia;Slovakia;Slovenia;United Kingdom
      2011   -   EUCTR2011-002912-10-SK   Germany;Hungary;Israel;Italy;Lithuania;Mexico;Netherlands;Poland;Romania;Serbia;Slovakia;Slovenia;United Kingdom;United States
      2011   -   EUCTR2011-002912-10-HU   Germany;Hungary;Israel;Italy;Lithuania;Mexico;Netherlands;Poland;Romania;Serbia;Slovakia;Slovenia;United Kingdom
      2011   -   EUCTR2011-002912-10-DE   Germany;Hungary;Israel;Italy;Lithuania;Mexico;Netherlands;Poland;Romania;Serbia;Slovakia;Slovenia;United Kingdom
   Endo Pharmaceuticals
      2007   Phase 2   NCT00913055   -
   Endo Pharmaceuticals Inc.
      2008   -   EUCTR2008-003327-23-DE   Czech Republic;Germany;Hungary;Poland;Spain
   Endo Pharmaceuticals Solutions
      2008   -   EUCTR2008-003327-23-CZ   Czech Republic;Hungary;Poland;Spain
   Endo Pharmaceuticals Solutions Inc
      2009   Phase 3   EUCTR2008-003327-23-SK   Czech Republic;Germany;Hungary;Poland;Slovakia;Spain
      2008   -   EUCTR2008-003327-23-HU   Czech Republic;Hungary;Poland;Spain
   Endo Pharmaceuticals Solutions Inc.
      2008   -   EUCTR2008-003327-23-PL   Czech Republic;Hungary;Poland;Spain
   ITALFARMACO S.p.A.
      2014   Phase 2   EUCTR2013-003183-31-RO   Czech Republic;France;Hungary;Italy;Netherlands;Poland;Romania;Spain
      2014   Phase 2   EUCTR2013-003183-31-PL   Czech Republic;France;Hungary;Italy;Netherlands;Poland;Romania;Serbia;Spain
      2014   Phase 2   EUCTR2013-003183-31-IT   Czech Republic;France;Hungary;Italy;Netherlands;Poland;Romania;Spain
      2014   Phase 2   EUCTR2013-003183-31-HU   Czech Republic;France;Hungary;Italy;Netherlands;Poland;Romania;Serbia;Spain
      2014   Phase 2   EUCTR2013-003183-31-CZ   Czech Republic;France;Hungary;Italy;Netherlands;Poland;Romania;Serbia;Spain
   Mallinckrodt Inc.
      2007   -   EUCTR2007-004162-41-HU   Hungary
   Novartis Pharmaceuticals
      2003   Phase 4   NCT00242541   Mexico
Octreotide acetate 30 MG suspension
   Novartis Pharmaceuticals
      2005   Phase 3   NCT00372697   Italy
Octreotide acetate and cabergoline/octrotide and somavert
   Novartis Pharmaceuticals
      2006   Phase 4   NCT00376064   Germany
Octreotide acetate microspheres FOR injection injection
   CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
      2023   Phase 1   NCT05761431   China
Octreotide acetate prolonged release, 30 MG
   Ambrilia Biopharma, Inc.
      2007   Phase 3   NCT00616551   Belarus;Former Serbia and Montenegro;Hungary;Romania;Serbia;Slovakia;Ukraine
Octreotide acetato
   CHIASMA INC.
      2016   Phase 3   EUCTR2015-002854-11-IT   Austria;Hungary;Italy;Lithuania;Poland;Spain;United States
Octreotide capsules
   Chiasma, Inc.
      2017   Phase 3   NCT03252353   Australia;Bulgaria;Canada;Denmark;Germany;Hungary;Israel;Italy;Latvia;Netherlands;New Zealand;Poland;Romania;Slovenia;Sweden;Turkey;United Kingdom;United States
      2016   Phase 3   NCT02685709   Austria;France;Germany;Hungary;Italy;Lithuania;Poland;Romania;Russian Federation;Serbia;Spain;United Kingdom;United States
      2012   Phase 3   NCT01412424   Germany;Hungary;Israel;Italy;Lithuania;Mexico;Netherlands;Poland;Romania;Serbia;Slovakia;Slovenia;United Kingdom;United States
Octreotide fluidcrystal® injection depot
   Camurus AB
      2015   Phase 2   NCT02299089   France;Germany;Italy;Sweden
Octreotide hydrochloride
   Camurus AB
      2020   Phase 3   EUCTR2019-002190-66-GB   Bulgaria;Germany;Greece;Hungary;Italy;Netherlands;Poland;Russian Federation;Serbia;Spain;Sweden;Turkey;United Kingdom;United States
      2020   Phase 3   EUCTR2019-002190-66-ES   Bulgaria;Germany;Greece;Hungary;Italy;Netherlands;Poland;Russian Federation;Serbia;Spain;Sweden;Turkey;United Kingdom;United States
      2020   Phase 3   EUCTR2019-002190-66-DE   Germany;Greece;Hungary;Italy;Poland;Russian Federation;Serbia;Spain;Türkiye;United Kingdom;United States
      2020   Phase 3   EUCTR2019-001191-11-GB   Bulgaria;Germany;Greece;Hungary;Italy;Netherlands;Poland;Russian Federation;Serbia;Spain;Sweden;Turkey;United Kingdom;United States
      2020   Phase 3   EUCTR2019-001191-11-ES   Bulgaria;Germany;Greece;Hungary;Italy;Netherlands;Poland;Russian Federation;Serbia;Spain;Sweden;Turkey;United Kingdom;United States
      2020   Phase 3   EUCTR2019-001191-11-DE   Germany;Greece;Hungary;Italy;Poland;Russian Federation;Spain;Sweden;Turkey;United Kingdom;United States
      2019   Phase 3   EUCTR2019-002190-66-PL   Germany;Greece;Hungary;Italy;Poland;Russian Federation;Serbia;Spain;Turkey;United Kingdom;United States
      2019   Phase 3   EUCTR2019-002190-66-HU   Bulgaria;Germany;Greece;Hungary;Italy;Netherlands;Poland;Russian Federation;Serbia;Spain;Sweden;Turkey;United Kingdom;United States
      2019   Phase 3   EUCTR2019-002190-66-GR   Germany;Greece;Hungary;Italy;Poland;Russian Federation;Serbia;Spain;Turkey;United Kingdom;United States
      2019   Phase 3   EUCTR2019-001191-11-PL   Bulgaria;Germany;Greece;Hungary;Italy;Netherlands;Poland;Russian Federation;Serbia;Spain;Sweden;Turkey;United Kingdom;United States
      2019   Phase 3   EUCTR2019-001191-11-HU   Bulgaria;Germany;Greece;Hungary;Italy;Netherlands;Poland;Russian Federation;Serbia;Spain;Sweden;Turkey;United Kingdom;United States
      2019   Phase 3   EUCTR2019-001191-11-GR   Germany;Greece;Hungary;Italy;Poland;Russian Federation;Spain;Sweden;Turkey;United Kingdom;United States
      2014   -   EUCTR2013-000533-12-IT   Germany;Italy
      2014   Phase 2   EUCTR2013-000533-12-DE   Germany;Italy
Octreotide implant
   Endo Pharmaceuticals
      2008   Phase 3   NCT00765323   Czech Republic;Germany;Hungary;Poland;Russian Federation;Serbia;Slovakia;Spain;United States
   Endo Pharmaceuticals Inc.
      2008   -   EUCTR2008-003327-23-DE   Czech Republic;Germany;Hungary;Poland;Spain
   Endo Pharmaceuticals Solutions
      2008   -   EUCTR2008-003327-23-CZ   Czech Republic;Hungary;Poland;Spain
   Endo Pharmaceuticals Solutions Inc
      2009   Phase 3   EUCTR2008-003327-23-SK   Czech Republic;Germany;Hungary;Poland;Slovakia;Spain
      2008   -   EUCTR2008-003327-23-HU   Czech Republic;Hungary;Poland;Spain
   Endo Pharmaceuticals Solutions Inc.
      2008   -   EUCTR2008-003327-23-PL   Czech Republic;Hungary;Poland;Spain
Octreotide LAR
   Cedars-Sinai Medical Center
      2012   -   NCT01538966   United States
   Kansai Study Groups for Hypothalamic and Pituitary Diseases
      2005   -   JPRN-C000000258   Japan
   New York University School of Medicine
      2004   Phase 4   NCT01371643   United States
   Novartis
      2002   Phase 3   NCT00128232   -
   Novartis Pharmaceuticals
      2002   Phase 3   NCT00225979   -
Octreotide LAR 30 MG injection
   Cedars-Sinai Medical Center
      2007   Phase 4   NCT00552071   United States
Octreotide LAR 30MG
   Novartis Pharmaceuticals
      2010   Phase 3   NCT01137682   Argentina;Belgium;Brazil;Canada;Colombia;France;Germany;Israel;Italy;Mexico;Norway;Poland;Romania;Russian Federation;Saudi Arabia;Spain;Turkey;United Kingdom;United States
Octreotide-LAR
   Federico II University
      1997   -   NCT00616408   Italy
      1995   Phase 4   NCT00461149   Italy
Octreotide-LAR or lanreotide
   Federico II University
      1997   -   NCT00703079   Italy
Ogtt
   Assistance Publique - Hôpitaux de Paris
      2019   -   NCT04066569   France
      2014   -   NCT02948322   France
   Cedars-Sinai Medical Center
      2011   -   NCT01371045   United States
ONO-5788
   Ono Pharmaceutical Co. Ltd
      2019   Phase 1   NCT03849872   Netherlands
      2018   Phase 1   NCT03571594   United States
Oral glucose tolerance test
   Cedars-Sinai Medical Center
      2011   -   NCT01371045   United States
      2008   -   NCT00915954   United States
      2006   -   NCT00921609   United States
Oral glucose tolerance testing
   Medical University of Vienna
      2014   -   NCT02115906   Austria
Paltusotine
   Crinetics Pharmaceuticals Inc.
      2021   Phase 3   NCT05192382   Argentina;Brazil;Bulgaria;China;France;Germany;Greece;Hungary;India;Israel;Italy;Poland;Spain;United Kingdom;United States
      2021   Phase 3   NCT04837040   Argentina;Austria;Belgium;Brazil;Bulgaria;France;Germany;Hungary;Israel;Italy;Peru;Poland;Russian Federation;Serbia;Spain;United Kingdom;United States
      2019   Phase 2   NCT04261712   Brazil;Greece;Hungary;Romania;Serbia;Slovakia;United Kingdom;United States
      2019   Phase 2   NCT03789656   Australia;Brazil;Germany;Greece;Hungary;Italy;New Zealand;Poland;Romania;Serbia;Slovakia;United Kingdom;United States
      2018   Phase 2   NCT03792555   Australia;Brazil;Germany;Greece;Hungary;Italy;New Zealand;Poland;Romania;Serbia;Slovakia;United Kingdom;United States
   Crinetics Pharmaceuticals, Inc.
      2022   Phase 3   EUCTR2021-001703-32-PL   Argentina;Brazil;Bulgaria;China;France;Germany;Greece;Hungary;India;Israel;Italy;Peru;Poland;Spain;United Kingdom;United States
      2022   Phase 3   EUCTR2021-001703-32-IT   Argentina;Brazil;Bulgaria;China;France;Germany;Greece;Hungary;India;Italy;Peru;Poland;Russian Federation;Spain;United Kingdom;United States
      2022   Phase 3   EUCTR2021-001703-32-GR   Argentina;Brazil;Bulgaria;China;France;Germany;Greece;Hungary;India;Israel;Italy;Peru;Poland;Spain;United Kingdom;United States
      2022   Phase 3   EUCTR2021-001703-32-ES   Argentina;Brazil;Bulgaria;China;France;Germany;Greece;Hungary;India;Italy;Peru;Poland;Russian Federation;Spain;United Kingdom;United States
      2022   Phase 3   EUCTR2021-001703-32-BG   Argentina;Brazil;Bulgaria;China;France;Germany;Greece;Hungary;India;Israel;Italy;Peru;Poland;Spain;United Kingdom;United States
      2022   Phase 3   EUCTR2020-005431-70-BE   Argentina;Austria;Belgium;Brazil;Bulgaria;France;Germany;Hungary;Israel;Italy;Peru;Poland;Russian Federation;Serbia;Spain;United Kingdom;United States
      2021   Phase 3   EUCTR2020-005431-70-PL   Argentina;Austria;Belgium;Brazil;Bulgaria;France;Germany;Hungary;Israel;Italy;Peru;Poland;Russian Federation;Serbia;Spain;United Kingdom;United States
      2021   Phase 3   EUCTR2020-005431-70-IT   Argentina;Austria;Belgium;Brazil;Bulgaria;France;Germany;Hungary;Israel;Italy;Peru;Poland;Russian Federation;Serbia;Spain;United Kingdom;United States
      2021   Phase 3   EUCTR2020-005431-70-HU   Argentina;Austria;Belgium;Brazil;Bulgaria;France;Germany;Hungary;Israel;Italy;Peru;Poland;Russian Federation;Serbia;Spain;United Kingdom;United States
      2021   Phase 3   EUCTR2020-005431-70-ES   Argentina;Austria;Belgium;Brazil;Bulgaria;France;Germany;Hungary;Israel;Italy;Peru;Poland;Russian Federation;Serbia;Spain;United Kingdom;United States
      2021   Phase 3   EUCTR2020-005431-70-DE   Argentina;Austria;Belgium;Brazil;Bulgaria;France;Germany;Hungary;Israel;Italy;Peru;Poland;Russian Federation;Serbia;Spain;United Kingdom;United States
      2021   Phase 3   EUCTR2020-005431-70-AT   Argentina;Austria;Belgium;Brazil;Bulgaria;France;Germany;Hungary;Israel;Italy;Peru;Poland;Russian Federation;Serbia;Spain;United Kingdom;United States
      2020   Phase 2   EUCTR2019-002193-31-SK   Brazil;Germany;Greece;Hungary;Serbia;Slovakia;United Kingdom;United States
      2020   Phase 2   EUCTR2019-002193-31-GR   Brazil;Germany;Greece;Hungary;Romania;Serbia;Slovakia;United Kingdom;United States
Paltusotine (free base)
   Crinetics Pharmaceuticals, Inc.
      2022   Phase 3   EUCTR2021-001703-32-HU   Argentina;Brazil;Bulgaria;China;France;Germany;Greece;Hungary;India;Italy;Peru;Poland;Russian Federation;Spain;United Kingdom;United States
      2021   Phase 3   EUCTR2020-005431-70-BG   Argentina;Austria;Belgium;Brazil;Bulgaria;France;Germany;Hungary;Israel;Italy;Peru;Poland;Russian Federation;Serbia;Spain;United Kingdom;United States
Pasireotida
   Novartis Farmacéutica, S. A
      2008   Phase 3   EUCTR2007-001972-36-ES   Belgium;Czech Republic;Denmark;France;Germany;Greece;Hungary;Italy;Netherlands;Poland;Portugal;Spain;Sweden;United Kingdom
Pasireotide
   Göteborgs Universitet, Göteborg Sweden
      2011   Phase 2   EUCTR2010-021008-77-SE   Italy;Netherlands;Sweden
   NOVARTIS FARMA
      2010   Phase 3   EUCTR2009-016722-13-IT   Belgium;France;Germany;Italy;Norway;Poland;Spain;United Kingdom
      2008   -   EUCTR2007-001972-36-IT   Belgium;Czech Republic;Denmark;France;Germany;Greece;Hungary;Italy;Netherlands;Poland;Portugal;Spain;Sweden;United Kingdom
      2005   -   EUCTR2004-002849-12-IT   Italy;Spain;United Kingdom
   NOVARTIS FARMA S.P.A.
      2016   Phase 3   EUCTR2014-002630-31-IT   Argentina;Belgium;Brazil;Bulgaria;China;Colombia;France;Germany;Hungary;Italy;Mexico;Portugal;Sweden;Turkey;United Kingdom;Venezuela, Bolivarian Republic of
   Novartis Farmaceutica S.A.
      2005   -   EUCTR2004-002849-12-ES   Italy;Spain;United Kingdom
   Novartis Farmacéutica, S.A.
      2015   Phase 4   EUCTR2013-000267-84-ES   Argentina;Australia;Belgium;Brazil;Bulgaria;Canada;China;France;Greece;Israel;Italy;Korea, Republic of;Mexico;Netherlands;Poland;Portugal;Russian Federation;Spain;Taiwan;Thailand;United States
      2010   Phase 3   EUCTR2009-016722-13-ES   Belgium;France;Germany;Italy;Norway;Poland;Spain;United Kingdom
   Novartis Pharma Services AG
      2016   Phase 3   EUCTR2014-002630-31-BG   Argentina;Belgium;Brazil;Bulgaria;China;Colombia;France;Germany;Hungary;Italy;Mexico;Portugal;Sweden;Turkey;United Kingdom;Venezuela, Bolivarian Republic of
      2016   Phase 4   EUCTR2013-000267-84-PL   Argentina;Australia;Belgium;Brazil;Bulgaria;Canada;China;France;Greece;Israel;Italy;Korea, Republic of;Mexico;Netherlands;Poland;Portugal;Russian Federation;Spain;Taiwan;Thailand;United States
      2015   Phase 3   EUCTR2014-002630-31-PT   Argentina;Belgium;Brazil;Bulgaria;China;Colombia;France;Germany;Hungary;Italy;Mexico;Portugal;Sweden;Turkey;United Kingdom;Venezuela, Bolivarian Republic of
      2015   Phase 3   EUCTR2014-002630-31-HU   Argentina;Belgium;Brazil;Bulgaria;China;Colombia;France;Germany;Hungary;Italy;Mexico;Portugal;Sweden;Turkey;United Kingdom;Venezuela, Bolivarian Republic of
      2015   Phase 3   EUCTR2014-002630-31-FR   Argentina;Belgium;Brazil;Bulgaria;China;Colombia;France;Germany;Hungary;Italy;Mexico;Portugal;Sweden;Turkey;United Kingdom;Venezuela, Bolivarian Republic of
      2015   Phase 3   EUCTR2014-002630-31-BE   Argentina;Belgium;Brazil;Bulgaria;China;Colombia;France;Germany;Hungary;Italy;Mexico;Portugal;Sweden;Turkey;United Kingdom;Venezuela, Bolivarian Republic of
      2012   Phase 3   EUCTR2009-016722-13-GB   Argentina;Belgium;Brazil;France;Germany;Israel;Italy;Mexico;Norway;Poland;Spain;United Kingdom;United States
      2011   Phase 3   EUCTR2009-016722-13-PL   Argentina;Belgium;Brazil;France;Germany;Israel;Italy;Mexico;Norway;Poland;Spain;United Kingdom;United States
      2011   Phase 3   EUCTR2009-016722-13-NO   Belgium;France;Germany;Italy;Norway;Poland;Spain;United Kingdom
      2010   Phase 3   EUCTR2009-016722-13-FR   Belgium;France;Germany;Italy;Norway;Poland;Spain;United Kingdom
      2010   Phase 3   EUCTR2009-016722-13-DE   Argentina;Belgium;Brazil;France;Germany;Israel;Italy;Mexico;Norway;Poland;Spain;United Kingdom;United States
      2010   Phase 3   EUCTR2009-016722-13-BE   Argentina;Belgium;Brazil;France;Germany;Israel;Italy;Mexico;Norway;Poland;Spain;United Kingdom;United States
      2009   -   EUCTR2007-001972-36-PT   Belgium;Czech Republic;Denmark;France;Germany;Greece;Hungary;Italy;Netherlands;Poland;Portugal;Spain;Sweden;United Kingdom
      2009   Phase 3   EUCTR2007-001972-36-GB   Belgium;Czech Republic;Denmark;France;Germany;Greece;Hungary;Italy;Netherlands;Poland;Portugal;Spain;Sweden;United Kingdom
      2008   Phase 3   EUCTR2007-001972-36-SE   Belgium;Czech Republic;Denmark;France;Germany;Greece;Hungary;Italy;Netherlands;Poland;Portugal;Spain;Sweden;United Kingdom
      2008   Phase 3   EUCTR2007-001972-36-PL   Belgium;Czech Republic;Denmark;France;Germany;Greece;Hungary;Italy;Netherlands;Poland;Portugal;Spain;Sweden;United Kingdom
      2008   Phase 3   EUCTR2007-001972-36-NL   Belgium;Czech Republic;Denmark;France;Germany;Greece;Hungary;Italy;Netherlands;Poland;Portugal;Spain;Sweden;United Kingdom
      2008   Phase 3   EUCTR2007-001972-36-HU   Belgium;Czech Republic;Denmark;France;Germany;Greece;Hungary;Italy;Netherlands;Poland;Portugal;Spain;Sweden;United Kingdom
      2008   Phase 3   EUCTR2007-001972-36-GR   Belgium;Czech Republic;Denmark;France;Germany;Greece;Hungary;Italy;Netherlands;Poland;Portugal;Spain;Sweden;United Kingdom
      2008   Phase 3   EUCTR2007-001972-36-FR   Belgium;Czech Republic;Denmark;France;Germany;Greece;Hungary;Italy;Netherlands;Poland;Portugal;Spain;Sweden;United Kingdom
      2008   -   EUCTR2007-001972-36-DK   Belgium;Czech Republic;Denmark;France;Germany;Greece;Hungary;Italy;Netherlands;Poland;Portugal;Spain;Sweden;United Kingdom
      2008   Phase 3   EUCTR2007-001972-36-DE   Belgium;Czech Republic;Denmark;France;Germany;Greece;Hungary;Italy;Netherlands;Poland;Portugal;Spain;Sweden;United Kingdom
      2008   Phase 3   EUCTR2007-001972-36-BE   Belgium;Czech Republic;Denmark;France;Germany;Greece;Hungary;Italy;Netherlands;Poland;Portugal;Spain;Sweden;United Kingdom
      2007   Phase 3   EUCTR2007-001972-36-CZ   Belgium;Czech Republic;Denmark;France;Germany;Greece;Hungary;Italy;Netherlands;Poland;Portugal;Spain;Sweden;United Kingdom
   Novartis Pharmaceuticals
      2010   Phase 3   NCT01137682   Argentina;Belgium;Brazil;Canada;Colombia;France;Germany;Israel;Italy;Mexico;Norway;Poland;Romania;Russian Federation;Saudi Arabia;Spain;Turkey;United Kingdom;United States
      2008   Phase 3   NCT00600886   Argentina;Australia;Belgium;Brazil;Canada;China;Colombia;Czech Republic;Czechia;Denmark;France;Germany;Greece;Hungary;Israel;Italy;Korea, Republic of;Mexico;Netherlands;Norway;Poland;Portugal;Russian Federation;Spain;Sweden;Switzerland;Taiwan;Turkey;United Kingdom;United States;Venezuela
      2006   Phase 1   NCT00446082   Belgium;Canada;Germany;Netherlands;Norway;United States
      2004   Phase 2   NCT00171730   Australia;Belgium;France;Germany;Italy;Switzerland;United States
      2004   Phase 2   NCT00088582   Australia;Belgium;France;Germany;Italy;Netherlands;Spain;Switzerland;United Kingdom;United States
   Novartis Pharmaceuticals UK Ltd
      2005   -   EUCTR2004-002849-12-GB   Italy;Spain;United Kingdom
Pasireotide 20MG
   Recordati AG
      2017   Phase 4   EUCTR2013-000267-84-PT   Argentina;Australia;Belgium;Brazil;Bulgaria;Canada;China;France;Greece;Israel;Italy;Korea, Republic of;Mexico;Netherlands;Poland;Portugal;Russian Federation;Spain;Taiwan;Thailand;United States
Pasireotide 40MG
   Recordati AG
      2017   Phase 4   EUCTR2013-000267-84-PT   Argentina;Australia;Belgium;Brazil;Bulgaria;Canada;China;France;Greece;Israel;Italy;Korea, Republic of;Mexico;Netherlands;Poland;Portugal;Russian Federation;Spain;Taiwan;Thailand;United States
Pasireotide 60MG
   Recordati AG
      2017   Phase 4   EUCTR2013-000267-84-PT   Argentina;Australia;Belgium;Brazil;Bulgaria;Canada;China;France;Greece;Israel;Italy;Korea, Republic of;Mexico;Netherlands;Poland;Portugal;Russian Federation;Spain;Taiwan;Thailand;United States
Pasireotide diaspartate
   Novartis Pharma Services AG
      2015   Phase 4   EUCTR2012-002916-16-PL   Belgium;China;Denmark;Germany;Poland;Russian Federation;Turkey;United States
      2015   Phase 4   EUCTR2012-002916-16-BE   Belgium;Brazil;Bulgaria;China;Denmark;Germany;India;Netherlands;Peru;Poland;Romania;Russian Federation;Spain;Thailand;Turkey;United States
      2014   Phase 4   EUCTR2012-002916-16-DK   Belgium;China;Denmark;Germany;Poland;Russian Federation;Turkey;United States
      2014   Phase 4   EUCTR2012-002916-16-DE   Belgium;China;Denmark;Germany;Poland;Russian Federation;Turkey;United States
Pasireotide LAR
   Erasmus Medical Centre
      2015   -   EUCTR2014-002219-41-NL   Netherlands
   Novartis Pharma Services AG
      2015   Phase 4   EUCTR2012-002916-16-PL   Belgium;China;Denmark;Germany;Poland;Russian Federation;Turkey;United States
      2015   Phase 4   EUCTR2012-002916-16-BE   Belgium;Brazil;Bulgaria;China;Denmark;Germany;India;Netherlands;Peru;Poland;Romania;Russian Federation;Spain;Thailand;Turkey;United States
      2014   Phase 4   EUCTR2012-002916-16-DK   Belgium;China;Denmark;Germany;Poland;Russian Federation;Turkey;United States
      2014   Phase 4   EUCTR2012-002916-16-DE   Belgium;China;Denmark;Germany;Poland;Russian Federation;Turkey;United States
   Novartis Pharmaceuticals
      2015   Phase 3   NCT02354508   Argentina;Belgium;Brazil;Bulgaria;China;Colombia;France;Hungary;Italy;Malaysia;Mexico;Portugal;Romania;Turkey;United Kingdom
      2014   Phase 4   NCT02060383   Belgium;Brazil;China;Denmark;Germany;India;Peru;Poland;Russian Federation;Thailand;Turkey;United States
      2012   Phase 2   NCT01673646   Japan
   RECORDATI GROUP
      2013   Phase 4   NCT01794793   Argentina;Belgium;Brazil;Bulgaria;Canada;China;France;Germany;Greece;Hungary;India;Israel;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;Peru;Poland;Portugal;Romania;Russian Federation;Spain;Switzerland;Taiwan;Thailand;Turkey;United States
Pasireotide LAR 60 MG
   Erasmus Medical Center
      2015   Phase 4   NCT02668172   Netherlands
Pasireotide long acting release formulation
   Novartis Pharmaceuticals
      2014   -   NCT01995734   United States
Pasireotide pamoate
   Novartis Pharma Services AG
      2015   Phase 4   EUCTR2012-002916-16-PL   Belgium;China;Denmark;Germany;Poland;Russian Federation;Turkey;United States
      2015   Phase 4   EUCTR2012-002916-16-BE   Belgium;Brazil;Bulgaria;China;Denmark;Germany;India;Netherlands;Peru;Poland;Romania;Russian Federation;Spain;Thailand;Turkey;United States
      2014   Phase 4   EUCTR2012-002916-16-DK   Belgium;China;Denmark;Germany;Poland;Russian Federation;Turkey;United States
      2014   Phase 4   EUCTR2012-002916-16-DE   Belgium;China;Denmark;Germany;Poland;Russian Federation;Turkey;United States
Pegvisomant
   BEAUFOUR IPSEN PHARMA
      2007   -   EUCTR2006-000297-72-IT   Czech Republic;Germany;Greece;Italy;Sweden;United Kingdom
   BEAUFOUR IPSEN Pharma
      2007   -   EUCTR2006-000297-72-SE   Czech Republic;Germany;Greece;Italy;Sweden;United Kingdom
      2007   Phase 3   EUCTR2006-000297-72-GR   Czech Republic;Denmark;Germany;Greece;Italy;Sweden;United Kingdom
      2007   Phase 3   EUCTR2006-000297-72-DK   Czech Republic;Denmark;Germany;Greece;Italy;Sweden;United Kingdom
      2007   -   EUCTR2006-000297-72-DE   Czech Republic;Germany;Greece;Italy;Sweden;United Kingdom
      2007   -   EUCTR2006-000297-72-CZ   Czech Republic;Germany;Greece;Italy;Sweden;United Kingdom
      2006   Phase 3   EUCTR2006-000297-72-GB   Czech Republic;Denmark;Germany;Greece;Italy;Sweden;United Kingdom
   Cedars-Sinai Medical Center
      2012   -   NCT01538966   United States
      2010   -   NCT01261000   United States
   Christie Hospital
      2008   -   EUCTR2006-000344-10-IE   Ireland;United Kingdom
      2006   Phase 4   EUCTR2006-000344-10-GB   Ireland;United Kingdom
      2005   Phase 4   EUCTR2004-004904-19-GB   United Kingdom
   Clinic of University of Wuerzburg
      2006   Phase 4   EUCTR2006-001108-35-DE   Germany
   Columbia University
      2016   -   NCT03225040   United States
   Department of Internal Medicine of the University of Munich
      2007   -   EUCTR2007-005585-12-DE   Germany
   Erasmus Medical Center
      2015   Phase 4   NCT02668172   Netherlands
      2006   Phase 4   NCT00642720   -
   Erasmus University Medical Centre Rotterdam
      2013   -   EUCTR2011-004231-31-NL   Netherlands
   Ipsen
      2006   Phase 3   NCT00383708   Czech Republic;Czechia;Denmark;France;Germany;Greece;Italy;Netherlands;Spain;Sweden;United Kingdom
   Ludwig-Maximilians - University of Munich
      2008   Phase 4   NCT00595140   Germany
   Max-Planck-Institut für Psychiatrie
      2018   Phase 4   EUCTR2014-000265-43-DE   Germany
   NOVARTIS FARMA
      2007   -   EUCTR2005-005852-42-IT   Italy;Portugal
   Novartis Pharma GmbH
      2006   -   EUCTR2005-002919-24-DE   Germany
   Novartis Pharma Services AG
      2008   -   EUCTR2005-005852-42-PT   Italy;Portugal
      2007   Phase 4   EUCTR2005-005852-42-BE   Belgium;Italy;Portugal
   Novartis Pharmaceuticals
      2006   Phase 4   NCT01278342   France;Italy;Poland;Portugal;Switzerland
   Pfizer
      2007   -   NCT00658879   -
      2004   Phase 3   NCT00143416   Japan
      2003   Phase 4   NCT00068042   Australia;Brazil;Canada;France;Germany;Greece;Ireland;Italy;Norway;Spain;Sweden;United Kingdom;United States
   Unity Health Toronto
      2017   Phase 3   NCT02952885   Canada
   University of Aarhus
      2008   -   NCT00652379   Denmark
   University of Wuerzburg
      2006   Phase 4   NCT00552851   Germany
   Österreichisches Akromegalie Register
      2014   -   EUCTR2010-023674-39-AT   Austria
Pegvisomant treatment
   Pfizer
      2004   Phase 4   NCT00151437   Canada
Pegvisomant/ sandostatin LAR
   Pfizer
      2003   Phase 4   NCT00068029   Australia;Brazil;Canada;France;Germany;Italy;Mexico;Netherlands;Norway;Spain;United Kingdom;United States
PHE
   Novartis Farmaceutica S.A.
      2005   -   EUCTR2004-002849-12-ES   Italy;Spain;United Kingdom
   Novartis Pharmaceuticals UK Ltd
      2005   -   EUCTR2004-002849-12-GB   Italy;Spain;United Kingdom
PN-800467
   Erasmus University Medical Centre Rotterdam
      2013   -   EUCTR2011-004231-31-NL   Netherlands
PRE-treatment with octreotide
   University Hospital, Rouen
      2005   -   NCT01029275   France
Preoperative lanreotide treatment
   Shanghai Jiao Tong University School of Medicine
      2004   Phase 2   NCT00993356   China
Radiotherapy
   Ginkgo Leaf Center for Rare Disorders
      2017   -   NCT03158090   China
   Huiwen Tan, Zhiyong Chen
      2017   -   ChiCTR-OOC-17013525   -
Raloxifene
   Christie Hospital NHS Trust
      2007   Phase 4   EUCTR2006-004989-14-GB   United Kingdom
Recombinant human growth hormone
   Massachusetts General Hospital
      2004   -   NCT00182091   United States
Rosiglitazone
   AZIENDA OSPEDALIERA PISANA
      2007   -   EUCTR2007-005568-28-IT   Italy
Saline
   Aspireo Pharmaceuticals Limited
      2013   Phase 2   NCT02217800   -
   Massachusetts General Hospital
      2004   -   NCT00182091   United States
Sandostatin
   Asan Medical Center
      2014   Phase 4   NCT02427295   Korea, Republic of
   Department of Internal Medicine of the University of Munich
      2007   -   EUCTR2007-005585-12-DE   Germany
   Ginkgo Leaf Center for Rare Disorders
      2017   -   NCT03158090   China
   Novartis Pharmaceuticals
      2004   Phase 2   NCT00088582   Australia;Belgium;France;Germany;Italy;Netherlands;Spain;Switzerland;United Kingdom;United States
Sandostatin LAR
   Aarhus University Hospital, Department M
      2008   -   EUCTR2007-005244-25-DK   Denmark
   Ambrilia Biopharma Inc.
      2007   Phase 3   EUCTR2006-005855-14-SK   Hungary;Slovakia
      2007   -   EUCTR2006-005855-14-HU   Hungary
   CHIASMA INC.
      2016   Phase 3   EUCTR2015-002854-11-IT   Austria;Hungary;Italy;Lithuania;Poland;Spain;United States
   Chiasma, Inc.
      2016   Phase 3   EUCTR2015-002854-11-RO   Austria;Canada;France;Germany;Hungary;Italy;Lithuania;Netherlands;Poland;Romania;Russian Federation;Serbia;Spain;United Kingdom;United States
      2016   Phase 3   EUCTR2015-002854-11-PL   Austria;Canada;France;Germany;Hungary;Italy;Lithuania;Netherlands;Poland;Romania;Russian Federation;Serbia;Spain;United Kingdom;United States
      2016   Phase 3   EUCTR2015-002854-11-NL   Austria;Canada;France;Germany;Hungary;Italy;Lithuania;Netherlands;Poland;Romania;Russian Federation;Serbia;Spain;United Kingdom;United States
      2016   Phase 3   EUCTR2015-002854-11-LT   Austria;France;Germany;Hungary;Italy;Lithuania;Netherlands;Poland;Romania;Russian Federation;Serbia;Spain;United Kingdom;United States
      2016   Phase 3   EUCTR2015-002854-11-HU   Austria;France;Germany;Hungary;Italy;Lithuania;Netherlands;Poland;Romania;Russian Federation;Serbia;Spain;United Kingdom;United States
      2016   Phase 3   EUCTR2015-002854-11-ES   Austria;Canada;France;Germany;Hungary;Italy;Lithuania;Netherlands;Poland;Romania;Russian Federation;Serbia;Spain;United Kingdom;United States
      2016   Phase 3   EUCTR2015-002854-11-DE   Austria;Canada;France;Germany;Hungary;Italy;Lithuania;Netherlands;Poland;Romania;Russian Federation;Serbia;Spain;United Kingdom;United States
      2016   Phase 3   EUCTR2015-002854-11-AT   Austria;France;Germany;Hungary;Italy;Lithuania;Netherlands;Poland;Romania;Russian Federation;Serbia;Spain;United Kingdom;United States
   Columbia University
      2006   Phase 4   NCT01424241   United States
   Debiopharm International SA
      2022   Phase 1   NCT05364944   Denmark;France;Germany;Hungary;Israel;Italy;Poland;Portugal;Russian Federation;Spain;Sweden;United Kingdom
   Endo Pharmaceuticals Inc.
      2008   -   EUCTR2008-003327-23-DE   Czech Republic;Germany;Hungary;Poland;Spain
   Endo Pharmaceuticals Solutions
      2008   -   EUCTR2008-003327-23-CZ   Czech Republic;Hungary;Poland;Spain
   Endo Pharmaceuticals Solutions Inc
      2009   Phase 3   EUCTR2008-003327-23-SK   Czech Republic;Germany;Hungary;Poland;Slovakia;Spain
      2008   -   EUCTR2008-003327-23-HU   Czech Republic;Hungary;Poland;Spain
   Endo Pharmaceuticals Solutions Inc.
      2008   -   EUCTR2008-003327-23-PL   Czech Republic;Hungary;Poland;Spain
   Novartis Pharma Services AG
      2011   Phase 3   EUCTR2009-016722-13-NO   Belgium;France;Germany;Italy;Norway;Poland;Spain;United Kingdom
      2008   Phase 3   EUCTR2007-001972-36-PL   Belgium;Czech Republic;Denmark;France;Germany;Greece;Hungary;Italy;Netherlands;Poland;Portugal;Spain;Sweden;United Kingdom
      2008   Phase 3   EUCTR2007-001972-36-GR   Belgium;Czech Republic;Denmark;France;Germany;Greece;Hungary;Italy;Netherlands;Poland;Portugal;Spain;Sweden;United Kingdom
      2008   -   EUCTR2005-005852-42-PT   Italy;Portugal
      2007   Phase 4   EUCTR2005-005852-42-BE   Belgium;Italy;Portugal
   Novartis Pharmaceuticals
      2006   Phase 4   NCT01278342   France;Italy;Poland;Portugal;Switzerland
   Pfizer
      2003   Phase 4   NCT00068042   Australia;Brazil;Canada;France;Germany;Greece;Ireland;Italy;Norway;Spain;Sweden;United Kingdom;United States
   Österreichisches Akromegalie Register
      2014   -   EUCTR2010-023674-39-AT   Austria
Sandostatin LAR 10 MG polvo para suspensióN inyectable
   Indevus Pharmaceuticals Incorporated
      2009   -   EUCTR2008-003327-23-ES   Czech Republic;Hungary;Poland;Spain
Sandostatin LAR 10MG
   Novartis Pharma Services AG
      2007   Phase 3   EUCTR2007-001972-36-CZ   Belgium;Czech Republic;Denmark;France;Germany;Greece;Hungary;Italy;Netherlands;Poland;Portugal;Spain;Sweden;United Kingdom
Sandostatin LAR 20 MG polvo para suspensióN inyectable
   Indevus Pharmaceuticals Incorporated
      2009   -   EUCTR2008-003327-23-ES   Czech Republic;Hungary;Poland;Spain
Sandostatin LAR 20MG
   Oxford Radcliffe Hospitals NHS trust
      2006   Phase 4   EUCTR2005-003496-20-GB   United Kingdom
Sandostatin LAR 20MG, 30MG
   Novartis Pharma Services AG
      2007   Phase 3   EUCTR2007-001972-36-CZ   Belgium;Czech Republic;Denmark;France;Germany;Greece;Hungary;Italy;Netherlands;Poland;Portugal;Spain;Sweden;United Kingdom
Sandostatin LAR 30 MG polvo para suspensióN inyectable
   Indevus Pharmaceuticals Incorporated
      2009   -   EUCTR2008-003327-23-ES   Czech Republic;Hungary;Poland;Spain
Sandostatin LAR 30MG
   Oxford Radcliffe Hospitals NHS trust
      2006   Phase 4   EUCTR2005-003496-20-GB   United Kingdom
Sandostatin LAR depot
   Endo Pharmaceuticals
      2008   Phase 3   NCT00765323   Czech Republic;Germany;Hungary;Poland;Russian Federation;Serbia;Slovakia;Spain;United States
Sandostatin LAR depot versus transsphenoidal surgery
   National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
      1999   Phase 2   NCT00001860   United States
Sandostatin LAR injection, 10MG, 20MG, 30MG
   Novartis Pharma Services AG
      2009   Phase 3   EUCTR2007-001972-36-GB   Belgium;Czech Republic;Denmark;France;Germany;Greece;Hungary;Italy;Netherlands;Poland;Portugal;Spain;Sweden;United Kingdom
Sandostatin LAR monatsdepot 20 MG
   Novartis Pharma GmbH
      2006   -   EUCTR2005-002919-24-DE   Germany
Sandostatin LAR ® (octreotide acetate LAR) 30 MG
   Azidus Brasil
      2010   Phase 1   NCT01086982   Brazil
Sandostatin LAR, 10 MG, 20 MG and 30 MG
   Novartis Pharma Services AG
      2008   Phase 3   EUCTR2007-001972-36-SE   Belgium;Czech Republic;Denmark;France;Germany;Greece;Hungary;Italy;Netherlands;Poland;Portugal;Spain;Sweden;United Kingdom
Sandostatin LAR-monatsdepot
   Novartis Pharma GmbH
      2006   -   EUCTR2005-002919-24-DE   Germany
Sandostatin LAR-monatsdepot 10 MG
   Novartis Pharma Services AG
      2008   Phase 3   EUCTR2007-001972-36-DE   Belgium;Czech Republic;Denmark;France;Germany;Greece;Hungary;Italy;Netherlands;Poland;Portugal;Spain;Sweden;United Kingdom
Sandostatin LAR-monatsdepot 20 MG
   Novartis Pharma Services AG
      2008   Phase 3   EUCTR2007-001972-36-DE   Belgium;Czech Republic;Denmark;France;Germany;Greece;Hungary;Italy;Netherlands;Poland;Portugal;Spain;Sweden;United Kingdom
Sandostatin LAR-monatsdepot 30 MG
   Novartis Pharma Services AG
      2008   Phase 3   EUCTR2007-001972-36-DE   Belgium;Czech Republic;Denmark;France;Germany;Greece;Hungary;Italy;Netherlands;Poland;Portugal;Spain;Sweden;United Kingdom
Sandostatin ® injection
   CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
      2023   Phase 1   NCT05761431   China
Sandostatina - LAR 20 MG/2.5 ML polvere E solvente PER sospensione iniettabile flacone polvere + siringa preriempita 2.5 ML + 2 aghi
   CHIASMA INC.
      2016   Phase 3   EUCTR2015-002854-11-IT   Austria;Hungary;Italy;Lithuania;Poland;Spain;United States
Sandostatina - LAR 30 MG/2.5 ML polvere E solvente PER sospensione iniettabile flacone polvere + siringa preriempita 2.5 ML + 2 aghi
   NOVARTIS FARMA S.P.A.
      2016   Phase 3   EUCTR2014-002630-31-IT   Argentina;Belgium;Brazil;Bulgaria;China;Colombia;France;Germany;Hungary;Italy;Mexico;Portugal;Sweden;Turkey;United Kingdom;Venezuela, Bolivarian Republic of
Sandostatina LAR
   NOVARTIS FARMA
      2010   Phase 3   EUCTR2009-016722-13-IT   Belgium;France;Germany;Italy;Norway;Poland;Spain;United Kingdom
      2008   -   EUCTR2007-001972-36-IT   Belgium;Czech Republic;Denmark;France;Germany;Greece;Hungary;Italy;Netherlands;Poland;Portugal;Spain;Sweden;United Kingdom
   Novartis Pharma Services AG
      2009   -   EUCTR2007-001972-36-PT   Belgium;Czech Republic;Denmark;France;Germany;Greece;Hungary;Italy;Netherlands;Poland;Portugal;Spain;Sweden;United Kingdom
Sandostatina LAR IM FL 20MG 2F
   NOVARTIS FARMA
      2007   -   EUCTR2005-005852-42-IT   Italy;Portugal
Sandostatine L.P. 30 MG, poudre ET solvant EN seringue
   Novartis Pharma Services AG
      2008   Phase 3   EUCTR2007-001972-36-FR   Belgium;Czech Republic;Denmark;France;Germany;Greece;Hungary;Italy;Netherlands;Poland;Portugal;Spain;Sweden;United Kingdom
Sandostatine L.P. 30 MG, poudre ET solvant pour suspension injectable à LIBération prolongéE
   Novartis Pharma Services AG
      2010   Phase 3   EUCTR2009-016722-13-FR   Belgium;France;Germany;Italy;Norway;Poland;Spain;United Kingdom
Sandostatine LAR 20 MG
   Novartis Pharma Services AG
      2007   Phase 4   EUCTR2005-005852-42-BE   Belgium;Italy;Portugal
Sandostatine long acting repeatable 30 MG
   Novartis Pharma Services AG
      2010   Phase 3   EUCTR2009-016722-13-BE   Argentina;Belgium;Brazil;France;Germany;Israel;Italy;Mexico;Norway;Poland;Spain;United Kingdom;United States
Sandostatin® LAR
   University of Aarhus
      2012   Phase 4   NCT01618513   Denmark
Sandostatin® LAR®-monatsdepot 10 MG
   Camurus AB
      2014   -   EUCTR2013-000533-12-IT   Germany;Italy
      2014   Phase 2   EUCTR2013-000533-12-DE   Germany;Italy
Sandostatin® LAR®-monatsdepot 20 MG
   Camurus AB
      2014   -   EUCTR2013-000533-12-IT   Germany;Italy
      2014   Phase 2   EUCTR2013-000533-12-DE   Germany;Italy
Sandostatin® LAR®-monatsdepot 30 MG
   Camurus AB
      2014   -   EUCTR2013-000533-12-IT   Germany;Italy
      2014   Phase 2   EUCTR2013-000533-12-DE   Germany;Italy
Sign and symptoms: questionnaire
   Pfizer
      2004   Phase 4   NCT00151437   Canada
Signifor
   Erasmus Medical Centre
      2015   -   EUCTR2014-002219-41-NL   Netherlands
   Novartis Farmacéutica, S.A.
      2015   Phase 4   EUCTR2013-000267-84-ES   Argentina;Australia;Belgium;Brazil;Bulgaria;Canada;China;France;Greece;Israel;Italy;Korea, Republic of;Mexico;Netherlands;Poland;Portugal;Russian Federation;Spain;Taiwan;Thailand;United States
   Novartis Pharma Services AG
      2016   Phase 4   EUCTR2013-000267-84-PL   Argentina;Australia;Belgium;Brazil;Bulgaria;Canada;China;France;Greece;Israel;Italy;Korea, Republic of;Mexico;Netherlands;Poland;Portugal;Russian Federation;Spain;Taiwan;Thailand;United States
      2015   Phase 3   EUCTR2014-002630-31-FR   Argentina;Belgium;Brazil;Bulgaria;China;Colombia;France;Germany;Hungary;Italy;Mexico;Portugal;Sweden;Turkey;United Kingdom;Venezuela, Bolivarian Republic of
      2015   Phase 4   EUCTR2012-002916-16-PL   Belgium;China;Denmark;Germany;Poland;Russian Federation;Turkey;United States
      2015   Phase 4   EUCTR2012-002916-16-BE   Belgium;Brazil;Bulgaria;China;Denmark;Germany;India;Netherlands;Peru;Poland;Romania;Russian Federation;Spain;Thailand;Turkey;United States
      2014   Phase 4   EUCTR2012-002916-16-DK   Belgium;China;Denmark;Germany;Poland;Russian Federation;Turkey;United States
      2014   Phase 4   EUCTR2012-002916-16-DE   Belgium;China;Denmark;Germany;Poland;Russian Federation;Turkey;United States
   Recordati AG
      2017   Phase 4   EUCTR2013-000267-84-PT   Argentina;Australia;Belgium;Brazil;Bulgaria;Canada;China;France;Greece;Israel;Italy;Korea, Republic of;Mexico;Netherlands;Poland;Portugal;Russian Federation;Spain;Taiwan;Thailand;United States
Sitagliptin
   Department of Medicine II, Hokkaido University Hospital
      2011   -   JPRN-UMIN000006516   Japan
   Novartis Pharmaceuticals
      2014   Phase 4   NCT02060383   Belgium;Brazil;China;Denmark;Germany;India;Peru;Poland;Russian Federation;Thailand;Turkey;United States
SMS995
   Novartis Farmacéutica, S. A
      2008   Phase 3   EUCTR2007-001972-36-ES   Belgium;Czech Republic;Denmark;France;Germany;Greece;Hungary;Italy;Netherlands;Poland;Portugal;Spain;Sweden;United Kingdom
   Novartis Farmacéutica, S.A.
      2010   Phase 3   EUCTR2009-016722-13-ES   Belgium;France;Germany;Italy;Norway;Poland;Spain;United Kingdom
   Novartis Pharma GmbH
      2006   -   EUCTR2005-002919-24-DE   Germany
   Novartis Pharma Services AG
      2012   Phase 3   EUCTR2009-016722-13-GB   Argentina;Belgium;Brazil;France;Germany;Israel;Italy;Mexico;Norway;Poland;Spain;United Kingdom;United States
      2011   Phase 3   EUCTR2009-016722-13-PL   Argentina;Belgium;Brazil;France;Germany;Israel;Italy;Mexico;Norway;Poland;Spain;United Kingdom;United States
      2011   Phase 3   EUCTR2009-016722-13-NO   Belgium;France;Germany;Italy;Norway;Poland;Spain;United Kingdom
      2010   Phase 3   EUCTR2009-016722-13-DE   Argentina;Belgium;Brazil;France;Germany;Israel;Italy;Mexico;Norway;Poland;Spain;United Kingdom;United States
      2010   Phase 3   EUCTR2009-016722-13-BE   Argentina;Belgium;Brazil;France;Germany;Israel;Italy;Mexico;Norway;Poland;Spain;United Kingdom;United States
      2009   -   EUCTR2007-001972-36-PT   Belgium;Czech Republic;Denmark;France;Germany;Greece;Hungary;Italy;Netherlands;Poland;Portugal;Spain;Sweden;United Kingdom
      2009   Phase 3   EUCTR2007-001972-36-GB   Belgium;Czech Republic;Denmark;France;Germany;Greece;Hungary;Italy;Netherlands;Poland;Portugal;Spain;Sweden;United Kingdom
      2008   Phase 3   EUCTR2007-001972-36-SE   Belgium;Czech Republic;Denmark;France;Germany;Greece;Hungary;Italy;Netherlands;Poland;Portugal;Spain;Sweden;United Kingdom
      2008   Phase 3   EUCTR2007-001972-36-PL   Belgium;Czech Republic;Denmark;France;Germany;Greece;Hungary;Italy;Netherlands;Poland;Portugal;Spain;Sweden;United Kingdom
      2008   Phase 3   EUCTR2007-001972-36-NL   Belgium;Czech Republic;Denmark;France;Germany;Greece;Hungary;Italy;Netherlands;Poland;Portugal;Spain;Sweden;United Kingdom
      2008   Phase 3   EUCTR2007-001972-36-HU   Belgium;Czech Republic;Denmark;France;Germany;Greece;Hungary;Italy;Netherlands;Poland;Portugal;Spain;Sweden;United Kingdom
      2008   Phase 3   EUCTR2007-001972-36-GR   Belgium;Czech Republic;Denmark;France;Germany;Greece;Hungary;Italy;Netherlands;Poland;Portugal;Spain;Sweden;United Kingdom
      2008   Phase 3   EUCTR2007-001972-36-FR   Belgium;Czech Republic;Denmark;France;Germany;Greece;Hungary;Italy;Netherlands;Poland;Portugal;Spain;Sweden;United Kingdom
      2008   -   EUCTR2007-001972-36-DK   Belgium;Czech Republic;Denmark;France;Germany;Greece;Hungary;Italy;Netherlands;Poland;Portugal;Spain;Sweden;United Kingdom
      2008   Phase 3   EUCTR2007-001972-36-DE   Belgium;Czech Republic;Denmark;France;Germany;Greece;Hungary;Italy;Netherlands;Poland;Portugal;Spain;Sweden;United Kingdom
      2008   Phase 3   EUCTR2007-001972-36-BE   Belgium;Czech Republic;Denmark;France;Germany;Greece;Hungary;Italy;Netherlands;Poland;Portugal;Spain;Sweden;United Kingdom
      2008   -   EUCTR2005-005852-42-PT   Italy;Portugal
      2007   Phase 3   EUCTR2007-001972-36-CZ   Belgium;Czech Republic;Denmark;France;Germany;Greece;Hungary;Italy;Netherlands;Poland;Portugal;Spain;Sweden;United Kingdom
      2007   Phase 4   EUCTR2005-005852-42-BE   Belgium;Italy;Portugal
SMS995B
   Novartis Pharma Services AG
      2008   -   EUCTR2005-005852-42-PT   Italy;Portugal
      2007   Phase 4   EUCTR2005-005852-42-BE   Belgium;Italy;Portugal
SOM022
   Christie Hospital
      2005   Phase 4   EUCTR2004-004904-19-GB   United Kingdom
SOM230
   Göteborgs Universitet, Göteborg Sweden
      2011   Phase 2   EUCTR2010-021008-77-SE   Italy;Netherlands;Sweden
   NOVARTIS FARMA
      2010   Phase 3   EUCTR2009-016722-13-IT   Belgium;France;Germany;Italy;Norway;Poland;Spain;United Kingdom
   NOVARTIS FARMA S.P.A.
      2016   Phase 3   EUCTR2014-002630-31-IT   Argentina;Belgium;Brazil;Bulgaria;China;Colombia;France;Germany;Hungary;Italy;Mexico;Portugal;Sweden;Turkey;United Kingdom;Venezuela, Bolivarian Republic of
   Novartis Farmacéutica, S.A.
      2015   Phase 4   EUCTR2013-000267-84-ES   Argentina;Australia;Belgium;Brazil;Bulgaria;Canada;China;France;Greece;Israel;Italy;Korea, Republic of;Mexico;Netherlands;Poland;Portugal;Russian Federation;Spain;Taiwan;Thailand;United States
      2010   Phase 3   EUCTR2009-016722-13-ES   Belgium;France;Germany;Italy;Norway;Poland;Spain;United Kingdom
   Novartis Pharma Services AG
      2016   Phase 3   EUCTR2014-002630-31-BG   Argentina;Belgium;Brazil;Bulgaria;China;Colombia;France;Germany;Hungary;Italy;Mexico;Portugal;Sweden;Turkey;United Kingdom;Venezuela, Bolivarian Republic of
      2016   Phase 4   EUCTR2013-000267-84-PL   Argentina;Australia;Belgium;Brazil;Bulgaria;Canada;China;France;Greece;Israel;Italy;Korea, Republic of;Mexico;Netherlands;Poland;Portugal;Russian Federation;Spain;Taiwan;Thailand;United States
      2015   Phase 3   EUCTR2014-002630-31-PT   Argentina;Belgium;Brazil;Bulgaria;China;Colombia;France;Germany;Hungary;Italy;Mexico;Portugal;Sweden;Turkey;United Kingdom;Venezuela, Bolivarian Republic of
      2015   Phase 3   EUCTR2014-002630-31-HU   Argentina;Belgium;Brazil;Bulgaria;China;Colombia;France;Germany;Hungary;Italy;Mexico;Portugal;Sweden;Turkey;United Kingdom;Venezuela, Bolivarian Republic of
      2015   Phase 3   EUCTR2014-002630-31-FR   Argentina;Belgium;Brazil;Bulgaria;China;Colombia;France;Germany;Hungary;Italy;Mexico;Portugal;Sweden;Turkey;United Kingdom;Venezuela, Bolivarian Republic of
      2015   Phase 3   EUCTR2014-002630-31-BE   Argentina;Belgium;Brazil;Bulgaria;China;Colombia;France;Germany;Hungary;Italy;Mexico;Portugal;Sweden;Turkey;United Kingdom;Venezuela, Bolivarian Republic of
      2012   Phase 3   EUCTR2009-016722-13-GB   Argentina;Belgium;Brazil;France;Germany;Israel;Italy;Mexico;Norway;Poland;Spain;United Kingdom;United States
      2011   Phase 3   EUCTR2009-016722-13-PL   Argentina;Belgium;Brazil;France;Germany;Israel;Italy;Mexico;Norway;Poland;Spain;United Kingdom;United States
      2011   Phase 3   EUCTR2009-016722-13-NO   Belgium;France;Germany;Italy;Norway;Poland;Spain;United Kingdom
      2010   Phase 3   EUCTR2009-016722-13-FR   Belgium;France;Germany;Italy;Norway;Poland;Spain;United Kingdom
      2010   Phase 3   EUCTR2009-016722-13-DE   Argentina;Belgium;Brazil;France;Germany;Israel;Italy;Mexico;Norway;Poland;Spain;United Kingdom;United States
      2010   Phase 3   EUCTR2009-016722-13-BE   Argentina;Belgium;Brazil;France;Germany;Israel;Italy;Mexico;Norway;Poland;Spain;United Kingdom;United States
      2009   -   EUCTR2007-001972-36-PT   Belgium;Czech Republic;Denmark;France;Germany;Greece;Hungary;Italy;Netherlands;Poland;Portugal;Spain;Sweden;United Kingdom
      2009   Phase 3   EUCTR2007-001972-36-GB   Belgium;Czech Republic;Denmark;France;Germany;Greece;Hungary;Italy;Netherlands;Poland;Portugal;Spain;Sweden;United Kingdom
      2008   Phase 3   EUCTR2007-001972-36-SE   Belgium;Czech Republic;Denmark;France;Germany;Greece;Hungary;Italy;Netherlands;Poland;Portugal;Spain;Sweden;United Kingdom
      2008   Phase 3   EUCTR2007-001972-36-PL   Belgium;Czech Republic;Denmark;France;Germany;Greece;Hungary;Italy;Netherlands;Poland;Portugal;Spain;Sweden;United Kingdom
      2008   Phase 3   EUCTR2007-001972-36-NL   Belgium;Czech Republic;Denmark;France;Germany;Greece;Hungary;Italy;Netherlands;Poland;Portugal;Spain;Sweden;United Kingdom
      2008   Phase 3   EUCTR2007-001972-36-HU   Belgium;Czech Republic;Denmark;France;Germany;Greece;Hungary;Italy;Netherlands;Poland;Portugal;Spain;Sweden;United Kingdom
      2008   Phase 3   EUCTR2007-001972-36-GR   Belgium;Czech Republic;Denmark;France;Germany;Greece;Hungary;Italy;Netherlands;Poland;Portugal;Spain;Sweden;United Kingdom
      2008   Phase 3   EUCTR2007-001972-36-FR   Belgium;Czech Republic;Denmark;France;Germany;Greece;Hungary;Italy;Netherlands;Poland;Portugal;Spain;Sweden;United Kingdom
      2008   -   EUCTR2007-001972-36-DK   Belgium;Czech Republic;Denmark;France;Germany;Greece;Hungary;Italy;Netherlands;Poland;Portugal;Spain;Sweden;United Kingdom
      2008   Phase 3   EUCTR2007-001972-36-DE   Belgium;Czech Republic;Denmark;France;Germany;Greece;Hungary;Italy;Netherlands;Poland;Portugal;Spain;Sweden;United Kingdom
      2008   Phase 3   EUCTR2007-001972-36-BE   Belgium;Czech Republic;Denmark;France;Germany;Greece;Hungary;Italy;Netherlands;Poland;Portugal;Spain;Sweden;United Kingdom
      2007   Phase 3   EUCTR2007-001972-36-CZ   Belgium;Czech Republic;Denmark;France;Germany;Greece;Hungary;Italy;Netherlands;Poland;Portugal;Spain;Sweden;United Kingdom
   Novartis Pharmaceuticals
      2004   Phase 2   NCT00088582   Australia;Belgium;France;Germany;Italy;Netherlands;Spain;Switzerland;United Kingdom;United States
   Recordati AG
      2017   Phase 4   EUCTR2013-000267-84-PT   Argentina;Australia;Belgium;Brazil;Bulgaria;Canada;China;France;Greece;Israel;Italy;Korea, Republic of;Mexico;Netherlands;Poland;Portugal;Russian Federation;Spain;Taiwan;Thailand;United States
SOM230 LAR
   Erasmus Medical Centre
      2015   -   EUCTR2014-002219-41-NL   Netherlands
   Novartis Pharma Services AG
      2015   Phase 4   EUCTR2012-002916-16-PL   Belgium;China;Denmark;Germany;Poland;Russian Federation;Turkey;United States
      2015   Phase 4   EUCTR2012-002916-16-BE   Belgium;Brazil;Bulgaria;China;Denmark;Germany;India;Netherlands;Peru;Poland;Romania;Russian Federation;Spain;Thailand;Turkey;United States
      2014   Phase 4   EUCTR2012-002916-16-DK   Belgium;China;Denmark;Germany;Poland;Russian Federation;Turkey;United States
SOM230 LAR, 20 MG
   Novartis Pharma Services AG
      2014   Phase 4   EUCTR2012-002916-16-DE   Belgium;China;Denmark;Germany;Poland;Russian Federation;Turkey;United States
SOM230, 300micrograms
   Novartis Pharma Services AG
      2014   Phase 4   EUCTR2012-002916-16-DE   Belgium;China;Denmark;Germany;Poland;Russian Federation;Turkey;United States
SOM230, 600 micrograms
   Novartis Pharma Services AG
      2014   Phase 4   EUCTR2012-002916-16-DE   Belgium;China;Denmark;Germany;Poland;Russian Federation;Turkey;United States
SOM230, 900 micrograms
   Novartis Pharma Services AG
      2014   Phase 4   EUCTR2012-002916-16-DE   Belgium;China;Denmark;Germany;Poland;Russian Federation;Turkey;United States
SOM230B
   NOVARTIS FARMA
      2005   -   EUCTR2004-002849-12-IT   Italy;Spain;United Kingdom
   Novartis Farmaceutica S.A.
      2005   -   EUCTR2004-002849-12-ES   Italy;Spain;United Kingdom
   Novartis Pharma Services AG
      2014   Phase 4   EUCTR2012-002916-16-DK   Belgium;China;Denmark;Germany;Poland;Russian Federation;Turkey;United States
   Novartis Pharmaceuticals UK Ltd
      2005   -   EUCTR2004-002849-12-GB   Italy;Spain;United Kingdom
SOM230C
   NOVARTIS FARMA
      2008   -   EUCTR2007-001972-36-IT   Belgium;Czech Republic;Denmark;France;Germany;Greece;Hungary;Italy;Netherlands;Poland;Portugal;Spain;Sweden;United Kingdom
   Novartis Farmacéutica, S. A
      2008   Phase 3   EUCTR2007-001972-36-ES   Belgium;Czech Republic;Denmark;France;Germany;Greece;Hungary;Italy;Netherlands;Poland;Portugal;Spain;Sweden;United Kingdom
   Novartis Farmacéutica, S.A.
      2010   Phase 3   EUCTR2009-016722-13-ES   Belgium;France;Germany;Italy;Norway;Poland;Spain;United Kingdom
   Novartis Pharma Services AG
      2014   Phase 4   EUCTR2012-002916-16-DK   Belgium;China;Denmark;Germany;Poland;Russian Federation;Turkey;United States
      2012   Phase 3   EUCTR2009-016722-13-GB   Argentina;Belgium;Brazil;France;Germany;Israel;Italy;Mexico;Norway;Poland;Spain;United Kingdom;United States
      2011   Phase 3   EUCTR2009-016722-13-PL   Argentina;Belgium;Brazil;France;Germany;Israel;Italy;Mexico;Norway;Poland;Spain;United Kingdom;United States
      2011   Phase 3   EUCTR2009-016722-13-NO   Belgium;France;Germany;Italy;Norway;Poland;Spain;United Kingdom
      2010   Phase 3   EUCTR2009-016722-13-FR   Belgium;France;Germany;Italy;Norway;Poland;Spain;United Kingdom
      2010   Phase 3   EUCTR2009-016722-13-DE   Argentina;Belgium;Brazil;France;Germany;Israel;Italy;Mexico;Norway;Poland;Spain;United Kingdom;United States
      2010   Phase 3   EUCTR2009-016722-13-BE   Argentina;Belgium;Brazil;France;Germany;Israel;Italy;Mexico;Norway;Poland;Spain;United Kingdom;United States
      2009   -   EUCTR2007-001972-36-PT   Belgium;Czech Republic;Denmark;France;Germany;Greece;Hungary;Italy;Netherlands;Poland;Portugal;Spain;Sweden;United Kingdom
      2008   Phase 3   EUCTR2007-001972-36-SE   Belgium;Czech Republic;Denmark;France;Germany;Greece;Hungary;Italy;Netherlands;Poland;Portugal;Spain;Sweden;United Kingdom
      2008   Phase 3   EUCTR2007-001972-36-PL   Belgium;Czech Republic;Denmark;France;Germany;Greece;Hungary;Italy;Netherlands;Poland;Portugal;Spain;Sweden;United Kingdom
      2008   Phase 3   EUCTR2007-001972-36-NL   Belgium;Czech Republic;Denmark;France;Germany;Greece;Hungary;Italy;Netherlands;Poland;Portugal;Spain;Sweden;United Kingdom
      2008   Phase 3   EUCTR2007-001972-36-HU   Belgium;Czech Republic;Denmark;France;Germany;Greece;Hungary;Italy;Netherlands;Poland;Portugal;Spain;Sweden;United Kingdom
      2008   Phase 3   EUCTR2007-001972-36-GR   Belgium;Czech Republic;Denmark;France;Germany;Greece;Hungary;Italy;Netherlands;Poland;Portugal;Spain;Sweden;United Kingdom
      2008   Phase 3   EUCTR2007-001972-36-FR   Belgium;Czech Republic;Denmark;France;Germany;Greece;Hungary;Italy;Netherlands;Poland;Portugal;Spain;Sweden;United Kingdom
      2008   -   EUCTR2007-001972-36-DK   Belgium;Czech Republic;Denmark;France;Germany;Greece;Hungary;Italy;Netherlands;Poland;Portugal;Spain;Sweden;United Kingdom
      2008   Phase 3   EUCTR2007-001972-36-DE   Belgium;Czech Republic;Denmark;France;Germany;Greece;Hungary;Italy;Netherlands;Poland;Portugal;Spain;Sweden;United Kingdom
      2008   Phase 3   EUCTR2007-001972-36-BE   Belgium;Czech Republic;Denmark;France;Germany;Greece;Hungary;Italy;Netherlands;Poland;Portugal;Spain;Sweden;United Kingdom
      2007   Phase 3   EUCTR2007-001972-36-CZ   Belgium;Czech Republic;Denmark;France;Germany;Greece;Hungary;Italy;Netherlands;Poland;Portugal;Spain;Sweden;United Kingdom
Somatostatin
   Chiasma, Inc.
      2016   Phase 3   NCT02685709   Austria;France;Germany;Hungary;Italy;Lithuania;Poland;Romania;Russian Federation;Serbia;Spain;United Kingdom;United States
   Huiwen Tan, Zhiyong Chen
      2017   -   ChiCTR-OOC-17013525   -
   Ionis Pharmaceuticals, Inc.
      2019   Phase 2   NCT03967249   Hungary;Lithuania;Poland;Romania;Russian Federation;Serbia;United States
   University of Aarhus
      2009   -   NCT01062529   Denmark
      2008   -   NCT00652379   Denmark
Somatulina autogel
   Beaufour Ipsen Pharma
      2008   -   EUCTR2007-000155-34-ES   Belgium;Czech Republic;Finland;France;Germany;Italy;Netherlands;Spain;Sweden;United Kingdom
Somatuline ATG
   Debiopharm International SA
      2022   Phase 1   NCT05364944   Denmark;France;Germany;Hungary;Israel;Italy;Poland;Portugal;Russian Federation;Spain;Sweden;United Kingdom
Somatuline autogel
   Beaufour Ipsen Pharma
      2008   -   EUCTR2007-005838-37-SE   Denmark;Finland;France;Greece;Latvia;Netherlands;Sweden
   CHIASMA INC.
      2016   Phase 3   EUCTR2015-002854-11-IT   Austria;Hungary;Italy;Lithuania;Poland;Spain;United States
   Chiasma, Inc.
      2016   Phase 3   EUCTR2015-002854-11-RO   Austria;Canada;France;Germany;Hungary;Italy;Lithuania;Netherlands;Poland;Romania;Russian Federation;Serbia;Spain;United Kingdom;United States
      2016   Phase 3   EUCTR2015-002854-11-PL   Austria;Canada;France;Germany;Hungary;Italy;Lithuania;Netherlands;Poland;Romania;Russian Federation;Serbia;Spain;United Kingdom;United States
      2016   Phase 3   EUCTR2015-002854-11-NL   Austria;Canada;France;Germany;Hungary;Italy;Lithuania;Netherlands;Poland;Romania;Russian Federation;Serbia;Spain;United Kingdom;United States
      2016   Phase 3   EUCTR2015-002854-11-LT   Austria;France;Germany;Hungary;Italy;Lithuania;Netherlands;Poland;Romania;Russian Federation;Serbia;Spain;United Kingdom;United States
      2016   Phase 3   EUCTR2015-002854-11-HU   Austria;France;Germany;Hungary;Italy;Lithuania;Netherlands;Poland;Romania;Russian Federation;Serbia;Spain;United Kingdom;United States
      2016   Phase 3   EUCTR2015-002854-11-ES   Austria;Canada;France;Germany;Hungary;Italy;Lithuania;Netherlands;Poland;Romania;Russian Federation;Serbia;Spain;United Kingdom;United States
      2016   Phase 3   EUCTR2015-002854-11-DE   Austria;Canada;France;Germany;Hungary;Italy;Lithuania;Netherlands;Poland;Romania;Russian Federation;Serbia;Spain;United Kingdom;United States
      2016   Phase 3   EUCTR2015-002854-11-AT   Austria;France;Germany;Hungary;Italy;Lithuania;Netherlands;Poland;Romania;Russian Federation;Serbia;Spain;United Kingdom;United States
   Ipsen
      2014   -   NCT02020499   Australia
      2007   Phase 3   NCT00447499   United States
   Medizinische Universität Wien, KIMIII, Abteilung für Endokrinologie und Stoffwechsel
      2014   -   EUCTR2013-004782-14-AT   Austria
   Österreichisches Akromegalie Register
      2014   -   EUCTR2010-023674-39-AT   Austria
Somatuline autogel 120
   BEAUFOUR IPSEN Pharma
      2007   -   EUCTR2006-000297-72-CZ   Czech Republic;Germany;Greece;Italy;Sweden;United Kingdom
Somatuline autogel 120 MG
   BEAUFOUR IPSEN Pharma
      2007   -   EUCTR2006-000297-72-SE   Czech Republic;Germany;Greece;Italy;Sweden;United Kingdom
      2007   -   EUCTR2006-000297-72-DE   Czech Republic;Germany;Greece;Italy;Sweden;United Kingdom
      2006   Phase 3   EUCTR2006-000297-72-GB   Czech Republic;Denmark;Germany;Greece;Italy;Sweden;United Kingdom
   Ipsen Pharma SAS
      2008   -   EUCTR2007-000155-34-DE   Belgium;Czech Republic;Finland;France;Germany;Italy;Netherlands;Spain;Sweden;United Kingdom
      2008   -   EUCTR2007-000155-34-CZ   Belgium;Czech Republic;Finland;France;Germany;Italy;Netherlands;Spain;Sweden;United Kingdom
      2008   Phase 3   EUCTR2007-000155-34-BE   Belgium;Czech Republic;Finland;France;Germany;Italy;Netherlands;Spain;Sweden;United Kingdom
Somatuline autogel 120MG
   Plymouth Hospital NHS Trust, R&D dept
      2006   Phase 2   EUCTR2005-004300-36-GB   United Kingdom
Somatuline autogel 60MG
   Plymouth Hospital NHS Trust, R&D dept
      2006   Phase 2   EUCTR2005-004300-36-GB   United Kingdom
Somatuline autogel 90MG
   Plymouth Hospital NHS Trust, R&D dept
      2006   Phase 2   EUCTR2005-004300-36-GB   United Kingdom
Somatuline autogel injectable 120
   Novartis Pharma Services AG
      2010   Phase 3   EUCTR2009-016722-13-BE   Argentina;Belgium;Brazil;France;Germany;Israel;Italy;Mexico;Norway;Poland;Spain;United Kingdom;United States
Somatuline autogel® 60, 90 or 120 MG
   Ipsen
      2012   -   NCT01840449   Austria;Germany;Switzerland
Somatuline L.P. 120 MG, solution injectable à LIBération prolongéE EN seringue PRéremplie
   Novartis Pharma Services AG
      2010   Phase 3   EUCTR2009-016722-13-FR   Belgium;France;Germany;Italy;Norway;Poland;Spain;United Kingdom
Somatuline LP 120MG
   Beaufour Ipsen Pharma
      2008   Phase 4   EUCTR2007-005838-37-FR   Denmark;Finland;France;Greece;Latvia;Netherlands;Sweden
Somatuline® autogel® 120 MG solution FOR injection
   Ipsen Pharma SAS
      2009   Phase 3   EUCTR2007-000155-34-GB   Belgium;Czech Republic;Finland;France;Germany;Italy;Netherlands;Spain;Sweden;United Kingdom
Somavert
   Aarhus University Hospital, Department M
      2008   -   EUCTR2007-005244-25-DK   Denmark
   Barts and the London NHS Trust
      2007   Phase 4   EUCTR2007-003741-33-GB   United Kingdom
   Christie Hospital
      2008   -   EUCTR2006-000344-10-IE   Ireland;United Kingdom
      2006   Phase 4   EUCTR2006-000344-10-GB   Ireland;United Kingdom
      2005   Phase 4   EUCTR2004-004904-19-GB   United Kingdom
   Department of Internal Medicine of the University of Munich
      2007   -   EUCTR2007-005585-12-DE   Germany
   Erasmus University Medical Centre Rotterdam
      2013   -   EUCTR2011-004231-31-NL   Netherlands
   Novartis Pharma GmbH
      2006   -   EUCTR2005-002919-24-DE   Germany
   Novartis Pharma Services AG
      2008   -   EUCTR2005-005852-42-PT   Italy;Portugal
   Pfizer
      2022   -   NCT05131100   Korea, Republic of
      2007   -   NCT00658879   -
   Österreichisches Akromegalie Register
      2014   -   EUCTR2010-023674-39-AT   Austria
Somavert 10 MG
   Clinic of University of Wuerzburg
      2006   Phase 4   EUCTR2006-001108-35-DE   Germany
Somavert 15 MG
   Clinic of University of Wuerzburg
      2006   Phase 4   EUCTR2006-001108-35-DE   Germany
   Novartis Pharma Services AG
      2007   Phase 4   EUCTR2005-005852-42-BE   Belgium;Italy;Portugal
Somavert 20 MG
   BEAUFOUR IPSEN PHARMA
      2007   -   EUCTR2006-000297-72-IT   Czech Republic;Germany;Greece;Italy;Sweden;United Kingdom
   BEAUFOUR IPSEN Pharma
      2007   -   EUCTR2006-000297-72-SE   Czech Republic;Germany;Greece;Italy;Sweden;United Kingdom
      2007   Phase 3   EUCTR2006-000297-72-GR   Czech Republic;Denmark;Germany;Greece;Italy;Sweden;United Kingdom
      2007   Phase 3   EUCTR2006-000297-72-DK   Czech Republic;Denmark;Germany;Greece;Italy;Sweden;United Kingdom
      2007   -   EUCTR2006-000297-72-DE   Czech Republic;Germany;Greece;Italy;Sweden;United Kingdom
      2007   -   EUCTR2006-000297-72-CZ   Czech Republic;Germany;Greece;Italy;Sweden;United Kingdom
      2006   Phase 3   EUCTR2006-000297-72-GB   Czech Republic;Denmark;Germany;Greece;Italy;Sweden;United Kingdom
   Clinic of University of Wuerzburg
      2006   Phase 4   EUCTR2006-001108-35-DE   Germany
   Max-Planck-Institut für Psychiatrie
      2018   Phase 4   EUCTR2014-000265-43-DE   Germany
   Novartis Pharma Services AG
      2007   Phase 4   EUCTR2005-005852-42-BE   Belgium;Italy;Portugal
Subcutaneous administration OF recombinant human IGF-1
   Cedars-Sinai Medical Center
      2008   -   NCT00915954   United States
Surgery FOR acromegaly
   Columbia University
      2003   -   NCT01809808   United States
SYHX2008 injection
   CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
      2023   Phase 1   NCT05761431   China
Tadalafil
   Andrea M. Isidori
      2016   Phase 2   NCT02611336   Italy
   UMBERTO I - POLICLINICO DI ROMA
      2016   Phase 2   EUCTR2015-004498-34-IT   Italy
TE-8214 - SAD
   Immunwork, Inc.
      2024   Phase 1   NCT06372652   Australia
Thyroid sonography
   Medical University of Vienna
      2014   -   NCT02115906   Austria
Total body magnetic resonance imaging
   Columbia University
      2003   -   NCT01809808   United States
Transcranial magnetic stimulation
   Huashan Hospital
      2020   -   NCT04529356   -
Transnasal butterfly surgery
   Ginkgo Leaf Center for Rare Disorders
      2017   -   NCT03158090   China
   Huiwen Tan, Zhiyong Chen
      2017   -   ChiCTR-OOC-17013525   -
Transsphenoidal adenomectomy
   Federico II University
      1997   -   NCT00703079   Italy
Transsphenoidal surgery
   New York University School of Medicine
      2004   Phase 4   NCT01371643   United States
   Shanghai Jiao Tong University School of Medicine
      2004   Phase 2   NCT00993356   China
TRP
   Novartis Farmaceutica S.A.
      2005   -   EUCTR2004-002849-12-ES   Italy;Spain;United Kingdom
   Novartis Pharmaceuticals UK Ltd
      2005   -   EUCTR2004-002849-12-GB   Italy;Spain;United Kingdom
TYR
   Novartis Farmaceutica S.A.
      2005   -   EUCTR2004-002849-12-ES   Italy;Spain;United Kingdom
   Novartis Pharmaceuticals UK Ltd
      2005   -   EUCTR2004-002849-12-GB   Italy;Spain;United Kingdom
UNK
   ITALFARMACO S.p.A.
      2014   Phase 2   EUCTR2013-003183-31-RO   Czech Republic;France;Hungary;Italy;Netherlands;Poland;Romania;Spain
      2014   Phase 2   EUCTR2013-003183-31-PL   Czech Republic;France;Hungary;Italy;Netherlands;Poland;Romania;Serbia;Spain
      2014   Phase 2   EUCTR2013-003183-31-IT   Czech Republic;France;Hungary;Italy;Netherlands;Poland;Romania;Spain
      2014   Phase 2   EUCTR2013-003183-31-HU   Czech Republic;France;Hungary;Italy;Netherlands;Poland;Romania;Serbia;Spain
      2014   Phase 2   EUCTR2013-003183-31-CZ   Czech Republic;France;Hungary;Italy;Netherlands;Poland;Romania;Serbia;Spain
Zoledronic acid
   Ruijin Hospital, Shanghai Jiao Tong University School of Medicine
      2024   -   ChiCTR2400091528   China